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ABSTRACT 
Objective: The literature regarding correlates of adjustment to cancer is abundant; 
however there has been no systematic review of the literature to identify which 
psychological variables are associated with adjustment specifically to stem cell 
transplantation.  The aim of this study was to identify the risk and protective factors 
for psychological adjustment to stem cell transplant. These factors can inform the 
development/implementation of specific interventions for this increasing population.     
 
Method: Five databases were systematically searched for quantitative research 
articles examining associative/predictive factors of adults’ psychological adjustment 
to Haematopoietic Stem Cell Transplantation (HSCT). A narrative synthesis was 
conducted. Studies were appraised for quality using the Downs & Black (1998) 
checklist for non-randomised studies.  
 
Results:  Eleven studies were identified reporting on a total of 2751 individuals. Seven 
studies were longitudinal and four were cross-sectional. All studies used correlation 
and/or regression approaches. A broad range of instruments were used to measure 
adjustment. No studies were rated as low quality. Evidence from moderate to high 
quality studies suggests that factors associated with poorer adjustment include 
avoidance-based coping strategies; high anxious preoccupation with the illness; lack 
of motivation to overcome the illness; low social support; high social constraint and 
pre-transplant distress/past psychiatric history. Factors associated with better 
adjustment include approach coping strategies, good social support, resilience, self-
efficacy, optimism, a sense of coherence and a sense of personal control.  
 
Conclusion: A psychosocial assessment should be performed at the point of diagnosis 
to identify individuals who may be at risk of poor post-transplant adjustment as a 
result of previous/current mental health, personality traits, coping style and level of 
support. The provision of interventions which enhance factors that are associated 
with good adjustment and modify factors associated with poor adjustment should be 
explored and made available to all potential transplant patients prior to commencing 
treatment. 
 
                            Keywords: psychological adjustment, stem cell transplant 
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INTRODUCTION 
A steady and gradual reduction in the mortality rate from cancer has occurred over 
the past few decades1. This is attributable to earlier detection rates and more effective 
medical interventions2. One intervention increasingly being used to treat a number of 
blood and bone marrow malignancies is haematopoietic stem cell transplantation, of 
which two types exist – autologous and allogeneic3. 
 
In an autologous transplant, stem cells are harvested from the patient. In an allogeneic 
transplant they are harvested from a donor. Prior to receiving the transplant, patients 
receive high dose chemotherapy and, occasionally, total body irradiation (TBI) both of 
which are used to destroy unhealthy blood cells. Stem cells are then placed back into 
the body whereby they find their way back to the bone marrow and begin to make 
healthy blood cells again4.  This is an increasingly successful treatment, however the 
intensity of the treatment has been found to cause considerable and prolonged 
distress, more so than might be experienced by other oncology patients with less 
intense treatment regimens3. Stressors include lengthy hospital stays, hospital 
readmission as a result of physical complications such as graft vs. host disease, fear of 
transplant failure and fear of death5.  These treatment-related stressors have been 
found to contribute to psychiatric morbidity beyond that reported in the general 
oncology population6. 
 
In the general oncology literature, approximately 40% of patients experience clinically 
significant levels of distress following cancer treatment7. This distress takes many 
forms including post-traumatic stress symptoms, depression and anxiety.  Prevalence 
of depression has been reported to be around 10-25%  by Cooke et al.6 and up to 40% 
by Carlson et al.8 .  The prevalence of anxiety and depression has been found to be 
four times greater than in the general population9,10.  Other researchers however have 
found anxiety and depression rates similar to those in non-patient populations11. 
 
Attempts to explain such differences in psychological adjustment to cancer has 
focused on demographic (age, sex, socio-economic status) medical (type of cancer, 
stage and severity of cancer and physical side effects) and psychosocial factors12. 
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Among the psychosocial factors, one consistent finding is that patients who consider 
themselves well supported experience less distress and greater wellbeing than those 
with little support13.  Another area of investigation includes dispositional factors such 
as coping styles and personality traits. In a study of advanced cancer patients, having 
controlled for functional status, Miller et al.14 found that optimism was strongly and 
positively associated with well-being and inversely related to distress, while avoidance 
coping was positively associated with distress.  Similarly, van’t Spiker et al’s.15 meta-
analysis found that approach coping strategies contribute to positive adjustment 
while avoidant coping is associated with poorer adjustment. Other factors reported to 
affect post-transplant adjustment include pre-transplant distress. Research in organ 
transplantation has shown that pre-transplant psychiatric disorders are significant 
predictors of poor post-transplant quality of life (QoL)16.  Similarly, high pre-surgery 
depression scores in breast cancer patients predict poorer post-surgical adjustment 
two years later17. 
 
Because of the unique nature of the transplant experience, HSCT patients may be 
more likely to experience a higher prevalence of distress (anxiety, depression and 
post-traumatic stress symptoms) at the pre-transplant stage when compared to other 
oncology populations6. A prevalence of 50% of pre-transplant global psychological 
distress has been documented in the transplant population compared to 30% outwith 
the transplant population18. This distress has been documented to persist for up to 5 
years post-transplant with up to 36% of patients reporting moderate to severe 
depressive symptoms during the first year following transplant19 and 19% reporting 
mild depressive symptoms at five years post-transplant20. The experience of such 
distress has been associated with decreased quality of life6. 
 
In view of the increasing success and use of stem cell transplantation, and the 
acknowledgment of the prevalence and longevity of distress in this population, it 
would be clinically beneficial to systematically review the literature on psychological 
risk and protective factors associated with psychological adjustment. A better 
understanding of these factors can help to identify those at risk of developing 
psychological morbidity. This can then inform the content of interventions to help 
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patients manage the psychological consequences they may experience as a result of 
the treatment.  
 
Although a broad concept, psychological adjustment can be described as 1) the 
absence of psychopathology such as anxiety, depression and trauma symptoms or 2) 
the presence of wellbeing as indicators of positive adaptation (e.g. self-esteem, self-
efficacy, quality of life and life satisfaction)21.  In addition, as social support has been 
conceptualised as a form of coping in that it aids individuals, when social support is 
measured as a factor associated with adjustment it will also be reported on22. 
 
Research question 
What psychological factors are associated with psychological adjustment following 
stem cell transplant?  
 
METHODS 
Search strategy 
Five databases (Medline, Embase, CINAHL, Psyc Info and the Cochrane Database) were 
searched in April 2016 by the researcher. Articles pertaining to psychological 
adjustment and stem cell transplant were identified by using the following search 
terms. These were developed in consultation with a librarian from the Greater 
Glasgow and Clyde Maria Henderson Library and with a clinician working in Oncology 
Services at the Beatson West of Scotland Cancer Centre (BWoSCC). Medical Subject 
Headings (MeSH) ‘bone marrow transplantation’ OR ‘hematopoietic stem cell 
transplantation’ were combined with keywords which included ‘bone marrow adj2 
transplant*’ OR ‘hematopoietic adj2 stem cell transplant*’ OR ‘haematopoietic adj2 
stem cell transplant*’. These terms were combined with MeSH terms ‘adaptation 
psychological’ OR ‘emotional adjustment’ OR ‘coping behaviour’ OR ‘mental stress’ 
and key words ‘emotional or psychological’ adj ‘wellbeing or coping’. The search was 
limited to adult human subjects and English language (See Appendix 1.2 for a full 
search strategy). 
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To increase the sensitivity of the search the reference lists of included studies were 
hand searched for further articles. No further articles were found following the hand 
search.  The researcher independently screened first by title, then by abstract and 
finally by reading the full text of articles. Studies that did not meet the inclusion 
criteria were excluded with reasons provided at the full text level.  See Figure 1 for an 
illustration of the systematic selection process. 
 
                               
 
 
 
     
 
   
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flow diagram of the systematic selection process. 
 
 
Cochrane Library 
(n=97) 
Psyc Info 
(n=32) 
Medline 
(n=1071) 
Embase 
(n=2039) 
Titles screened: 
(n=3311) 
Excluded following 
review of title: 
(n=3199) 
Abstracts transferred 
to Refworks: 
(n=112) 
Duplicates removed:  
(n=16) 
Abstracts screened  
(n=96) 
Full text of articles 
reviewed for eligibility: 
(n=19) 
Articles included in 
review: 
(n=11)  
Excluded following 
review of abstract: 
(n=77) 
Full texts excluded  
(n=8) 
Psychological adjustment 
not the outcome variable 
(n=1) 
No transplant procedure 
(n=1) 
Examining predictors of 
distress prior to transplant 
procedure (n=4) 
Risk factors for poor 
adjustment are not 
psychological (n=2)  
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Inclusion and exclusion criteria 
Articles were included if they explored psychological variables associated with 
psychological adjustment (consistent with the definition given in the introduction) to 
a bone marrow transplant (BMT) or haematopoietic stem cell transplant; were 
published in English, using quantitative methods and published in a peer reviewed 
journal. Articles were excluded if there was no reference to transplant procedure as 
part of the cancer treatment e.g. chemotherapy only; if no measures of psychological 
adjustment were reported; if only non-psychological (i.e. physical and demographic) 
variables were studied as associates of adjustment; if they employed qualitative 
methods and if they were reviews, case studies, dissertations or conference 
proceedings. See Appendix 1.3 for reasons for exclusion at the full text level. 
 
Data extraction and quality assessment 
It is accepted that there is no one single approach to assessing quality that is 
appropriate for all types of systematic review23. The Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) suggests using a domain approach 
that illustrates common sources of bias that may influence results.  A modified version 
of the checklist developed by Downs and Black (1998)24 was used to assess the 
methodological quality of the included studies (Appendix 1.4).  The National 
Collaborating Centre for Methods and Tools has recognised this as a valid and reliable 
quality rating tool for non-randomised studies25. In addition, a systematic review of 
the methodological quality of assessment tools for non-experimental studies reported 
that Downs and Black (1998) checklist assesses five of the six content domains 
considered essential when assessing methodological quality (with the exception of 
funding) and it is suitable cross-sectional designs26. 
 
No experimental studies were included in this review; therefore, nine of the 27 
questions relating to intervention studies were removed from the checklist (questions 
4, 7, 8, 13, 14, 15, 19, 23, and 24). This left 18 items which were given a score of ‘1’ if 
the study met the criteria and ‘0’ if the study did not, or if it was not possible to 
determine whether the study met the criteria based on the information provided.  
Following these modifications, the maximum possible score was 18.  Articles with a 
score of ≥14 (75% of the maximum attainable score) were classified as high quality, 
those with a score of 9-13 (50-74%) were classified as moderate quality and those with 
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a score of ≤8 (below 50%) were classified as low quality. Inter-rater reliability was 
achieved by having an independent rater review 55% of the included papers (n=6). 
Overall agreement was 91%. Any disagreements were resolved through discussion 
(See Appendix 1.5 for quality ratings of included studies). 
 
RESULTS 
Participant Characteristics  
The studies reported on 2751 patients who had undergone BMT or HSCT (1414 males, 
1337 females). Rosenberg et al.27 who recruited 1823 patients skews this number. 
Ages ranged from 18-76, although Hochhausen et al.28 did not report age ranges.  One 
thousand and forty-eight patients received an autologous transplant, 1632 received 
an allogeneic transplant. Goetzman et al.29 did not report the transplant type. 
Ethnicity was not reported by four studies29-32. When ethnicity was reported, the 
majority were white (n=2186). 
 
Assessment of psychological adjustment  
Psychological adjustment was measured in a number of different ways in the included 
studies. These include the absence of anxiety, depression, anger, uncertainty and 
PTSD symptoms; presence of quality of life, life satisfaction, social and emotional 
wellbeing and self-efficacy. As a result, there was considerable variability in the 
instruments used to measure adjustment. Fourteen different measures were used, 
four more commonly. Four studies used the PTSD Checklist Civilian Version (PCL-C)33-
36; three studies used the Hospital Anxiety and Depression Scale (HADS)31-33; three 
studies used the Medical Outcomes Short Form-36 27,29,34 and two studies used the 
Centre for Epidemiological Studies of Depression (CES-D)28,37. (See Appendix 1.6 for a 
full list of outcome measures used). Due to the heterogeneous nature of the studies 
identified in terms of description and measurement of adjustment and study design, 
a narrative synthesis was considered more appropriate than a meta-analysis. 
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Study characteristics and methodological quality 
Among the studies, four were cross-sectional 27,31,35,36 and seven were 
longitudinal28,29,30,32,33,34,37.  Warchala et al.32 did not report the time points examined, 
only reported ‘pre and post BMT’.  No studies were conducted in the UK. The quality 
of studies ranged from 13-18, with a median of 15. Two studies received ‘moderate 
quality’ scores30,32.  The remaining nine studies received ‘high quality’ scores 
27,28,29,31,33,34,35,36,37.  
 
Methodological shortcomings in both ‘moderate quality’ studies arose from being 
unable to determine the representativeness of the population. This was owing to a 
lack of information regarding the proportion of people who were asked to participate 
but declined, compared to the proportion who were asked to participate and agreed 
to take part. As the characteristics of those who did not take part were not described, 
it was not possible to determine if those invited versus those recruited differed in any 
way. In addition, it was also unclear if potential confounding variables such as medical 
and demographic factors were investigated or controlled for in the analysis. 
Furthermore, there was a lack of clarity from Warchala et al.32 regarding how long 
after transplant follow up took place and if this was the same for all participants. One 
of Fife et al’s.30 main findings was not presented in a table making it difficult to 
determine the importance of its contribution and its meaning in the context of the 
other results.  
 
Synthesis of findings 
 
Social support  
Six studies examined relationship between social support and adjustment. A lower 
perception of support pre-transplant was associated with increased PTSD symptom 
severity post-transplant34 as was an increased perception of social constraint (an 
unsupportive environment)36.  Low social support was also predictive of poor general 
life satisfaction at one year post-transplant29.   Good social support was a predictor of 
emotional wellbeing and reduced post-transplant depression28, negatively correlated 
with post-transplant depression30 (the availability of material aid in particular)37 and 
associated with reduced anxiety, anger and uncertainty30.  
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Coping strategies 
Five studies examined the relationship between coping strategy and adjustment. Two 
studies found an association between avoidant coping (behavioural disengagement, 
denial, distraction36 cognitive avoidance, resignation, seeking alternative rewards)34 
and PTSD symptom severity.  The remaining three studies found a relationship 
between avoidant coping on post-transplant anxiety30 and depression,32,37. Wells et 
al.37 found that post-transplant anxiety was positively correlated with the use of 
avoidance coping, in particular, resignation. Similarly, Warchala et al.32 found that 
post-transplant anxiety was significantly predicted by pre-transplant lower ‘fighting 
spirit’ (motivation regarding overcoming the illness). Post-transplant depression was 
predicted by lower ‘fighting spirit’ and high anxious preoccupation regarding the 
illness pre-transplant. Conversely, depression was negatively correlated with 
approach coping strategies such as problem solving37 and positive reframing30.  
 
Jacobson et al.34 found an interaction between coping and social support. At high 
levels of avoidance coping, those with low social support had more severe PTSD 
symptoms than those who were high in both avoidance coping and high in social 
support. This accounted for 7% of the variance in PTSD symptoms not already 
explained by social support, avoidance coping and psychological distress mentioned 
above.  Conversely, at a low level of avoidance coping there was no significant 
relationship between social support and PTSD symptom severity.  
 
Pre-transplant distress/past psychiatric history 
Five studies examined the relationship between pre-transplant distress or psychiatric 
history on adjustment. Two studies found that a past psychiatric history (anxiety or 
mood disorder) was associated with increased severity of PTSD symptoms post-
transplant34,36.  Jacobson et al.34 found that this accounted for 30% of the variability in 
PTSD symptom severity. Two studies found that those most distressed pre-transplant 
(anxiety and anger) continued to be most distressed at post-transplant30 and those 
most distressed pre-transplant (anxiety and depression) continued to be most 
distressed post-transplant when compared to non-distressed patients (81% vs 13%)33.  
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Goetzman et al.29 found that pre-transplant distress was predictive of poor general life 
satisfaction post-transplant. 
 
Optimism 
Two studies examined the relationship between optimism and adjustment. Results 
revealed that high optimism pre-transplant is a significant predictor of low anxiety29 
and depression28,29 and higher social and emotional wellbeing post-transplant28.   
 
Resilience 
Two cross-sectional studies examined the relationship between resilience and 
adjustment. They found a negative relationship between resilience and anxiety and 
depression27,31 and a positive relationship between resilience and mental health 
related QoL, global QoL and self-efficacy31.  Furthermore, individuals grouped as 
‘highly resilient’ based on a median split were found to have higher QoL, emotional 
functioning, self-efficacy and lower anxiety and depression than less resilient 
individuals31. 
 
Sense of coherence/global meaning 
Two studies examined the relationship between a sense of coherence, a concept that 
Park and Folkman (1997) labelled ‘global meaning’ defined as “the general sense that 
one’s life has purpose and coherence” on adjustment (Johnson-Vickberg et al.35 p.30). 
They found that global meaning was inversely related to anxiety and depression29,35,  
inversely related to BMT related distress (PTSD symptoms associated with 
transplantation)35 and positively related35/predictive29 of low anxiety and depression 
post-transplant. 
 
Self-efficacy  
Hochhausen et al.28 found that higher self-efficacy was a significant predictor of social 
and emotional wellbeing and lower depression severity one year post-transplant. 
 
Personal control 
Fife et al.30 found that personal control accounted for 50% of the variance in anxiety, 
depression, anger and uncertainty at one year post-transplant. 
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Table 1.  Summary of factors associated with psychological adjustment  
Associated factors  Post-transplant adjustment  
Pre-transplant: 
 avoidance coping  
 low social support 
 high social constraint 
 distress (anxiety, depression)  
Past psychiatric history (anxiety or mood disturbance) 
Increased PTSD 
Pre-transplant sense of coherence/global meaning Decreased PTSD 
Pre-transplant: 
 avoidance coping  
 anxiety 
 low fighting spirit  
Post-transplant anxious pre-occupation 
Increased anxiety 
Resilience  
Pre and during transplant personal control 
Pre-transplant: 
 Social support 
 Optimism 
 Sense of coherence/global meaning 
Decreased anxiety  
Pre-transplant: 
 Depression 
 low fighting spirit 
Post-transplant high anxious preoccupation 
Increased depression 
Pre-transplant: 
 approach coping  
 social support 
 optimism 
 sense of coherence/global meaning 
 self-efficacy 
Pre and during transplant personal control 
Resilience 
Decreased depression 
Resilience Increased quality of life 
Resilience  Increased self-efficacy 
Pre transplant: 
 Anxiety  
 Depression 
 Low social support 
Decreased life satisfaction 
Pre-transplant: 
 Social support 
 optimism  
 self-efficacy 
Increased social/emotional 
wellbeing 
Pre and during transplant personal control 
During transplant family support 
Pre-transplant approach coping 
Decreased anger 
Pre and during transplant personal control 
During transplant family support 
Pre-transplant approach coping 
Decreased uncertainty 
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Although the focus of this review was to determine what factors are associated with 
post-transplant adjustment, two studies examined factors associated with pre-
transplant distress. Given that the included studies have found an association 
between pre-transplant distress and post-transplant adjustment, these findings are 
worth noting. Warchala et al.32 found that pre-transplant anxiety was predicted by 
high anxious pre-occupation, low ‘fighting spirit’ and low optimism. These factors 
accounted for 51% of variation in pre-transplant anxiety. Similarly, pre-transplant 
depression was predicted by low global quality of life and low ‘fighting spirit’, 
accounting for 36% of variation in pre-transplant depression.  Wells et al.37 found that 
higher avoidance coping and lower social support explained 24% of the variance in 
pre-transplant depression and 26% of the variance in pre-transplant anxiety. 
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Table 2. Data extraction table of studies investigating psychological factors associated with psychological adjustment following stem cell transplant. 
Author, year  
origin 
Quality 
rating  
Sample characteristics  Design /  
Measurement points 
Psychological 
adjustment outcome 
measure  
Associated factors 
measures 
Results  
Fife et al. 
(2000)    
USA 
13/18 N=100 
Male -67 
Female–33 
Age range–20-59 
 
Autologous-78 
Allogeneic-22 
 
Multi-site 
Longitudinal  
T1– baseline pre-
transplant 
T2–1-2 days pre-
transplant 
T3-7 days post-
transplant 
T4–14 days post-
transplant 
T5–1 month post-
transplant 
T6–3 months post-
transplant 
T7–1 year post-
transplant 
Depression, anger, 
anxiety, uncertainty 
(Bi-Polar POMS) 
Perception of social 
support  
(PFPFSS + HCPSS) 
 
Coping style 
(WCC) 
 
Perception of personal 
control in life  
(Mastery Scale) 
 
Perception of impact of 
transplant on life (MIS) 
 
 
-Greater personal control, associated with reduced anxiety, depression 
anger and uncertainty from T3 to T7. 
 -Individuals most distressed at baseline were most distressed 1 year 
post-transplant (anxiety r=0.28 and anger r=0.40 only)  
At time points T3/T4:  
-avoidant coping associated with increased anxiety. 
-approach coping (positive re-framing) associated with reduced 
depression, anger, uncertainty.  
-family support associated with reduced anxiety, depression, anger, 
uncertainty. 
 
Goetzmann et 
al. (2007)  
Germany 
15/18  N=76 (28 BMT patients) 
Male–49 
Female–27 
 
Age range 18-67 
 
Single centre 
 
 
Longitudinal  
T1–2 days prior to 
hospital stay 
T2–1 year post-
transplant 
Overall quality of life 
mental health subscale 
(SF-36) 
 
Questions on Life 
Satisfaction 
questionnaire 
 
 
Extent to which it is 
believed ones 
environment is 
predictable/explicable 
and resources can meet 
demands (S0C-13)  
 
Optimism (LOT)  
 
Anxiety and depression 
(HADS) 
 
Perceived and 
anticipated social 
support (F-SozU) 
-high sense is of coherence pre-transplant is predictive of better mental 
health (ẞ=0.36) post-transplant. 
-high optimism pre-transplant is a predictor of good mental health post-
transplant (ẞ=0.26). 
-anxiety (ẞ=0.37) depression (ẞ=-0.30) and low social support (ẞ=0.39) 
are predictors of poor general life satisfaction post-transplant. 
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Author, year  
origin 
Quality 
rating  
Sample characteristics  Design /  
Measurement points 
Psychological 
adjustment outcome 
measure  
Associated factors 
measures 
Results  
Hochhausen 
et al. (2007) 
USA 
14/18 N=87 
Male-46 
Female–41 
 
All allogeneic 
 
Multi-site 
 
 
Longitudinal  
T1–Baseline (four days 
prior to transplant 
T2–1 year post-
transplant 
Depression  
(CES-D) 
 
Health Related Quality 
of Life in cancer 
patients (FACT –G) 
 
Social support (MOS) 
 
 
Optimism (LOT) 
 
Self-efficacy (CBI-L) 
-higher social support (ẞ=0.368), higher optimism (ẞ=0.256), higher self-
efficacy (ẞ=0.417) all significant predictors of HRQoL and lower scores 
on the CES-D (ẞ=-.370), (ẞ=-0.235) and (ẞ=-0.422) respectively. 
 
 
 
 
 
Jacobson et 
al. (2002) 
USA 
14/18 N=70 
Male-16 
Female-54 
Age 23-65 
 
White non-hispanic – 
93% 
 
Autologous–83% 
Allogeneic–17%  
 
Country-USA 
 
Site not reported 
 
 
 
 
 
 
 
 
Longitudinal  
T1-1 month pre-
transplant 
T2–5 months post-
transplant 
DSM-IV PTSD symptom 
criteria (PCL-C) 
 
 
 
 
Coping responses (CRI) 
 
Psychological distress 
(anxiety, depression, 
anger) (POMS) 
 
Social support (ISEL-SF) 
-Higher  avoidance coping (β=0.24) and lower social support (β-0.26) 
pre-transplant related to increased PTSD symptom severity. 
-Higher psychological distress pre-transplant (β=0.55) related to greater 
PTSD symptom severity.  
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Author, year  
origin 
Quality 
rating  
Sample characteristics  Design /  
Measurement points 
Psychological 
adjustment outcome 
measure  
Associated factors 
measures 
Results  
Lee et al. 
(2005) 
USA 
15/18 N=61  
Male-31 
Female–30 
Age range 20-72 
 
White- 60 
 
Autologous–27 
Allogeneic–34 
 
Single centre 
Longitudinal 
T1-Prior to hospital 
admission 
T2–first clinic visit after 
discharge 
T3–100 days post-
transplant 
 
Depression (BDI-II) 
 
Anxiety and depression  
(HADS) 
 
DSM-IV PTSD symptom 
criteria (PCL-C) 
 
 
 
Depression (BDI-II) 
 
Anxiety and depression  
(HADS) 
 
DSM-IV PTSD symptom 
criteria (PCL-C) 
 
 
 
 
-38 pre-transplant assessments returned – 21 (55%) in distressed range 
for anxiety and/or depression at pre-transplant. 
 
-Of the 21 distressed pre-transplant, 13/16 (81%) were still distressed 
post-transplant. 
-Of the 17 non-distressed 2 of 16 (13%) had become distressed. 
Therefore, those distressed pre-transplant are more likely to screen for 
distress post-transplant (81 vs 13%). 
 
 
 
Rosenberg et 
al. (2015)  
USA 
16/18 N=1823 
Male-957  
Female–866 
Age range-24-76 
 
White–1646 
Asian–68 
African/American–47 
Non-hispanic-1737 
Hispanic–47 
 
Autologous-672 
Allogeneic-1151 
Total body irradiation 
(TBI)–795 
No TBI-952 
 
Single centre  
 
 
 
Cross-sectional Overall quality of life 
mental health subscale 
(SF-36) 
 
Anxiety, depression, 
cancer related distress  
(CTD) 
 
 
Resilience (CDRS) -resilience scores correlated with psychological distress  (r=-0.51) and 
HRQoL composite score (r=0.62).  
-each additional resilience point associated with 0.8 higher mental 
composite score. 
-individuals reporting  lowest quartile of resilience scores had the 
highest odds of psychological distress (odds ratio, 3.0; 95% CI, 2.1-4.3). 
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Author, year  
origin 
Quality 
rating  
Sample characteristics  Design /  
Measurement points 
Psychological 
adjustment outcome 
measure  
Associated factors 
measures 
Results  
Warchala et 
al. (2015) 
Poland 
13/18 N=60  
Male-26 
Female–34 
 
All allogeneic 
transplants 
 
Single centre 
 
Longitudinal 
Time points not 
reported 
Anxiety and depression 
(HADS) 
Acceptance of Illness 
(AIS) 
 
Anger, depression, 
anxiety expression 
(CECS) 
 
Coping responses in 
patients with cancer 
(MAC) 
 
Optimism (LOT) 
 
 
-pre-transplant anxiety predicted by high anxious preoccupation 
(ẞ=0.23) low ‘fighting spirit’ (ẞ=-0.20) and low optimism (ẞ=-0.09). These 
explained 51% of variation in pre-transplant anxiety (R²=0.51). 
-post-transplant anxiety predicted by pre-transplant anxiety (ẞ=0.43), 
low pre-transplant ‘fighting spirit’, (ẞ=-0.10) and post-transplant high 
‘anxious preoccupation’ (ẞ=0.05) These explained 77% of variation in 
post-transplant anxiety (R²=0.77). 
-pre-transplant depression predicted by low ‘fighting spirit’ (ẞ=0.14), 
low global quality of life (ẞ=0.22). These explained 36% of variation in 
pre-transplant depression (R²=0.36). 
-post-transplant depression predicted by low pre-transplant ‘fighting 
spirit’ (ẞ=0.14), high pre-transplant depression (ẞ=0.07) high post-
transplant ‘anxious preoccupation’ (ẞ=0.38), low post-transplant global 
QoL (ẞ-=0.10) and low pre-transplant QoL (ẞ=0.12). These  explained 
81% of variation in depression post-transplant (R²=0.81). 
Wells et al. 
(2009)  
USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16/18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N=212 
Male–113 
Female–101 
(discrepancy here) 
Age range 21-73 
 
White non-Hispanic-
181 
African american-20 
Hispanic-11 
 
Autologous-172 
Allogeneic-42 
 
Single centre  
 
 
 
Longitudinal 
T1–pre-transplant 
T2–6 months post-
transplant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Depression  
(CES-D) 
 
Anxiety (STAI –SAS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coping responses (CRI) 
 
Social support (ISEL-SF) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coping: 
-pre-transplant depression  positively correlated with cognitive 
avoidance (r=0.23) resignation (r=0.32) and negatively correlated with 
problem solving (r=-0.15). 
-pre-transplant anxiety positively correlated with cognitive avoidance 
(r=0.33) and resignation (r=0.36). 
-post transplant anxiety was positively correlated with resignation 
(r=0.19). 
 
Support: 
-pre-transplant depression negatively correlated with tangible (r=-0.29) 
appraisal (r=-0.25)  belonging support (r=-0.25) 
-pre-transplant anxiety negatively correlated with tangible (r=-0.27) 
appraisal (r=-0.21) belonging support (r=-0.24) 
-post-transplant depression negatively correlated with tangible support 
(r=-0.15). 
 
 
20 
 
Author, year  
origin 
Quality 
rating 
Sample characteristics 
 
Design /  
Measurement points 
Psychological 
adjustment outcome 
measure 
 
Associated factors 
measures 
Results 
 
 
 
Support & coping 
-higher resignation (ẞ=0.27), lower problem solving (ẞ=-0.18), lower 
perception of tangible (ẞ=-0.16) and belonging support (ẞ=-0.13) 
associated with increased depression pre-transplant.  
-higher resignation (ẞ=0.25) higher cognitive avoidance (ẞ=0.16) and 
lower tangible (ẞ=-0.14) and belonging (ẞ=-0.17) support associated 
with increased pre-transplant anxiety.  
 
Widows et al. 
(2000)  
USA 
18/18 N=102 
Mal-23 
Female-79 
Age range  21-70  
 
White–91% 
 
Allogeneic–17% 
Autologous–83% 
 
Single centre  
Cross-sectional Assessment of Axis 1 
psychiatric disorders on 
DSM-IV criteria non-
patient edition  (SCID-
I/NP) 
 
 
DSM-IV PTSD symptom 
criteria (PCL-C) 
 
 
 
 
Coping styles (Brief 
COPE) 
 
Social support (ISEL-SF) 
 
Perception of 
constraint in discussing 
thoughts and feelings 
with others (SCS) 
 
Perceptions of trauma 
associated with BMT 
(TEQ – developed for 
this study) 
Past psychiatric history 
Individuals with history of anxiety/mood disorder pre-transplant, 
reported greater PTSD severity (M=33.22, SD12.48) than participants 
with no history (M=28.36, SD 9.01), t=-2.16. 
 
Coping 
increased use of avoidance based coping related to increased PTSD 
severity–behavioural disengagement (r=0.34)  self-distraction (r=0.21), 
denial  (r=0.39). 
 
Social support 
-Decreased perceptions of social support related to increased PTSD 
severity -tangible (r=-0.36), appraisal (r=-0.21), and belonging support 
(r=-0.41). 
-increased perceptions of social constraint from a significant other 
(r=0.28) and other people (r=0.39) related to higher PTSD severity. 
All reported results were indicated to be statistically significant in original articles at p<0.05 level or below. 
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DISCUSSION 
This is the first systematic review of the literature to identify psychological factors 
associated with post-transplant psychological adjustment to stem cell transplant.  
Factors associated with poorer adjustment i.e. an increase in psychological distress 
include avoidance-based coping strategies; high preoccupation with the illness; lack of 
motivation to overcome the illness; lack of social support and pre-transplant 
distress/past psychiatric history. Factors associated with better adjustment include good 
social support, resilience, self-efficacy, optimism, a sense of coherence and a sense of 
personal control.  
 
Methodological critique of included studies 
Limitations of the studies included relatively small sample sizes, apart from Rosenberg 
et al.27 whose sample accounted for over 50% of all participants in the review. Patient 
attrition is a problem commonly found in studies of cancer patients, often owing to 
symptom burden or mortality38. Participant attrition resulted in only 48% of Fife et al’s.30 
sample completing final questionnaires, 47% of Goetzman et al’s.29 and 45% of Lee et 
al’s.33 sample.  Attrition also arose from a desire not to take part.  Participants reported 
no longer wanting to think about it30 or wanting to move on35. Similarly, a number of 
participants eligible to take part chose not to34. Although the majority of studies 
determined that there were no significant differences between participants and non-
participants with regards to demographic and medical factors (type of cancer, length of 
hospitalisation, transplant type) it is uncertain if there were differences between groups 
with regards to psychological variables. Together, these factors indicate a potential 
selection bias in that those who declined to take part and those who opted out during 
the study may have been experiencing greater distress. Furthermore, this may mean 
that those in most need of intervention are not being captured by research. 
 
In addition, these relatively small samples comprise individuals with various diagnoses. 
Of those who reported cancer type, 18 types were reported, comprising individuals who 
had received different transplant types (autologous or allogeneic) and treatment 
regimens (chemotherapy and/or TBI). It is possible that different intensity of treatment 
regimens contribute to variability in the psychological adjustment of patients. For 
example, one might expect an individual who has undergone high dose conditioning 
chemotherapy, TBI and an allogeneic transplant (which is associated with a higher 
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incidence of mortality) to experience more distress. Predominantly single centre studies 
with little racial diversity and largely from the USA also limit the generalizability of the 
findings to individuals who have undergone stem cell transplantation from other ethnic 
groups and in other countries.   
 
Four included studies were cross-sectional, all of which were rated as high quality. These 
studies found moderate to large relationships between resilience, a sense of coherence, 
avoidance coping and social support on psychological adjustment, however it is 
impossible to infer causality in these studies. These results do not illustrate whether low 
resilience predisposes an individual to poor adjustment, or whether poor adjustment 
affects self-reported resilience at that time point. Furthermore, it is possible that these 
variables are related owing to shared associations with another unmeasured variable. 
Nevertheless, these associations now identified can be more rigorously studied using 
longitudinal designs. The data collection points in the cross sectional studies also varied 
considerably in the time period since transplantation, between 3 months36 to 11 years35. 
Therefore psychological status may have been impacted by a number of life 
events/environmental stressors in the preceding months and years and cannot be solely 
attributed to BMT/HSCT. Widows et al.36 attempted to account for prior 
psychopathology and/or life events which may contribute to psychological adjustment 
by using the Structured Clinical Interview for DSM-IV (SCID) to assess lifetime and 
current psychiatric diagnoses. They requested that participants separately consider their 
experiences of cancer diagnosis and treatment when responding to questions in order 
to distinguish PTSD symptoms related to their cancer experience from those related to 
other traumatic experiences. 
 
Limitations of current review 
This review noted heterogeneity in the measurement and description of psychological 
adjustment. Owing to the limited research in this area, it was not possible to limit the 
included studies to only those which defined psychological adjustment in one way e.g. 
absence of depression or to those which measured adjustment using one outcome 
measure e.g. BDI-II. Greater consistency regarding instruments used to measure 
adjustment would facilitate comparison across studies or the combination of results in 
a meta-analysis. A meta-analysis would help to overcome the small sample sizes in 
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cancer research therefore increasing the power to detect effect and in turn, provide a 
rational for the design/implementation of interventions to target those variables.  
 
Conclusions 
Consistent with previous general oncology literature, the current review found that 
good social support and optimism pre-transplant was associated with reduced distress 
post-transplant i.e. better adjustment, while avoidance coping was associated with 
increased distress i.e. poorer adjustment. The current findings also reflect those of organ 
transplantation research which found that pre-transplant psychiatric history and pre-
surgery depression scores are associated with low post-transplant quality of life and 
poorer post-surgical adjustment respectively16.   Additionally, one moderate quality32 
and one high quality37 study found that pre-transplant depression and anxiety were 
associated with high anxious pre-occupation, low motivation regarding overcoming the 
illness, low optimism, low global quality of life, low social support and high avoidance 
coping.  
 
Recommendations for future research and practice 
The finding that personal dispositions such as optimism and coping styles are associated 
with pre-transplant distress and that past psychiatric history and pre-transplant distress 
contribute to poorer post-transplant adjustment, together, suggest that it may be 
beneficial for all patients undergoing this treatment to complete a psychiatric history,  
routine screening for current psychological distress and an assessment of personality 
characteristics. This might identify those who are at risk of poor adjustment who can 
then be monitored and offered support throughout the treatment journey. Social 
support was consistently associated with better adjustment which highlights the need 
for a psychosocial assessment and provision of social support via health, social care and 
third sector services where required.  Larger samples would enable more homogenous 
groups’ to be studied e.g. comparing adjustment of allogeneic and autologous transplant 
patients to determine if different transplant/treatment regimens differentially affects 
adjustment. This systematic review has identified the factors associated with 
psychological adjustment to BMT/HSCT. Following on from this, the use of qualitative 
methods may help determine in what ways and in what context these factors are 
important and contribute to adjustment. This would also omit the use of commonly used 
self-report measures which are not specifically developed for this population.  
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Plain English Summary 
 
Caregivers’ Experiences and Coping Strategies Relating to Patient’s 
Subjective Treatment-Related Cognitive Impairment following 
Haematopoietic Stem Cell Transplant (HSCT)  
 
Background 
The treatments involved in cancers of the blood and bone marrow, such 
as stem cell transplantation can be physically and psychologically 
challenging and be associated with side effects such as memory and 
concentration difficulties, known as “chemo brain” (Evans & Eschiti, 
2009). The severity of these side effects varies widely but when it 
occurs, it can significantly impact the patient’s quality of life by 
interfering with their daily activities, relationships and future plans. 
Cancer has been described as a “family disease” which indicates that 
these challenges are also faced by the patients’ loved ones. This has 
prompted a great deal of research exploring caregivers’ experiences of 
caring for a loved one with cancer, however, no research so far has 
explored caregivers’ experiences related specifically to the cognitive 
effects or “chemo brain” their loved one has experienced following 
stem cell transplantation. 
 
Aims 
The aims of this study were to investigate caregivers’ experiences of the 
cognitive effects in their loved ones who have undergone stem cell 
transplant, how they coped with their experiences and what supports 
they believe could help.  
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Methods 
The study involved interviewing five participants (all female caregivers) 
and asking them to describe their experiences. Two participants 
requested a face-to-face interview and three requested a telephone 
interview. The interviews were audio-recorded and then typed up word 
for word. This was then analysed for experiences shared by participants. 
 
Findings  
The results illustrated 4 main themes shared by participants.  
1. Noticing change. Caregivers’ experienced increasing recognition 
of their spouse’s memory difficulty which initially went 
unnoticed. This was also accompanied by an increasing 
recognition of a change in their spouse’s behaviour. This included 
a lack of confidence in themselves and a desire to isolate 
themselves.  
2. Managing expectations. Caregivers’ experienced uncertainty 
about their future. There was concern regarding how the 
changes in their spouse would affect their lives. Caregivers dealt 
with this uncertainty by planning for the future, trying to prevent 
deterioration of their spouse’s memory and trying to keep their 
day-to-day lives as normal as possible. 
3. Managing personal feelings. Caregivers’ experienced a sense of 
loss. Loss of their partner, loss of friendships and loss of 
aspirations for the future. They also experienced frustration with 
their spouse’s limitations. They dealt with this frustration by 
reminding themselves the limitations were not their spouse’s 
fault. They also coped with these feelings by talking to others, 
distracting themselves and making the most of their time 
together. 
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4. Commitment. Despite experiences of uncertainty, loss and 
frustration, there was a sense of enduring responsibility to their 
spouses. 
 
Conclusions 
The “next steps” booklet that patients receive explaining long term 
effects of HSCT could be supplemented with a discussion with patients 
and their partners/family members about potential late side effects of 
treatment, such as changes in memory and behaviour. This might help 
caregivers to feel more prepared and reduce the uncertainty they 
experience.  Caregivers and patients are likely to have different needs, 
therefore future research should consider exploring the experiences of 
individuals as a couple in order to identify any mutual needs, where 
interventions are likely to create optimum impact.  
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ABSTRACT 
 
The treatments involved in cancers of the blood and bone marrow can be physically 
and psychologically challenging and be associated with adverse secondary effects, 
including cognitive impairment. The incidence and severity of treatment-related 
cognitive impairment varies widely, however it can significantly impact quality of life 
by interfering with patients’ activities of daily living, relationships and future plans. It 
can also pose challenges for the patients’ caregivers, an area which has received 
comparatively less research attention. The aim of this study was to investigate 
caregivers’ experiences of treatment-related cognitive impairment in patients who 
have undergone Haematopoietic Stem Cell Transplant (HSCT); how they coped, both 
practically and emotionally, and what supports they believe could help them. 
Participants were caregivers to individuals who had undergone HSCT within the past 
20 years and who had reported cognitive changes at the HSCT Late Effects Clinic, 
Beatson West of Scotland Cancer Centre. Five participants completed a single semi-
structured interview. The data was then analysed using Interpretative 
Phenomenological Analysis (IPA).  Results of this analysis illustrated four super-
ordinate themes: noticing change; managing expectations, managing personal 
feelings and commitment. Findings from the current study highlighted the 
importance of caregiver education regarding post HSCT cognitive and behavioural 
changes and providing caregiver emotional support. Future research should explore 
the mutual needs of both care recipient and caregiver. 
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INTRODUCTION 
 
More than one in three people in the UK will develop some form of cancer during 
their lifetime, of which there are more than 200 types, each with different causes, 
symptoms and treatments1.  For many cancers, the treatments involved can be 
physically and psychologically challenging and associated with lasting adverse 
secondary effects2. 
 
Approximately 26,700 cases of the three most common blood cancers (leukaemia, 
lymphoma and myeloma) are diagnosed in the UK every year, 94% of which occur in 
adults1.  Haematopoietic Stem Cell Transplant (HSCT) can be used to treat these 
diseases. Allogeneic stem cell transplant involves transferring stem cells from a 
healthy person (the donor) to the affected individual following their conditioning 
therapy (high-intensity chemotherapy and/or total body irradiation). This treatment 
is highly burdensome. Even an ‘uncomplicated’ allogeneic HSCT may involve up to 4 
weeks hospitalization and up to 4 months outpatient management3. Physical and 
psychological recovery may take several years for HSCT recipients and for some, cure 
of the cancer may not be accompanied by full restoration of health4.  
 
In addition to physical complications, patients may experience cognitive difficulties, 
often referred to as “chemo brain”5 (p.661) long after their treatment has ended. 
Changes commonly occur in the domains of executive functioning, memory and 
attention6.  For some patients, cognitive impairment is present up to twenty years 
following treatment7. This is most often seen in patients who require high dose 
chemotherapy and/or total body irradiation8.  The exact incidence of its occurrence 
is unknown, however at present it is estimated that treatment-related cognitive 
impairment affects between 17-78%7.   Changes can occur as early as the first 
chemotherapy session and/or accumulate and develop over subsequent 
treatments9.  
 
In a two year prospective study of cognitive functioning on 242 HSCT recipients and 
98 healthy controls, Bosworth and Bhatia10 found that executive functioning, 
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processing speed and verbal fluency were all significantly worse in HSCT participants. 
With regards to the duration of symptoms, Booth-Jones et al.11 examined patients six 
months after HSCT, finding at least mild cognitive deficits in 51% and moderate to 
severe impairment in 28%.  As evident in the aforementioned studies, for those who 
do develop treatment-related cognitive impairment, the duration and severity are 
highly variable. Nevertheless, even mild cognitive difficulties can have practical and 
psychological consequences9. Jim et al’s.12 study exploring what patients’ wish they 
had known about quality of life following allogeneic HSCT revealed a desire for 
education about late effects as these were experienced as unexpected and were 
reported to have significantly impacted their quality of life.  One respondent noted 
“...that’s what I am hoping will come out of this [study], is that you have support 
groups that would focus on key areas: neurological side effects, orthopaedic side 
effects, you know, mental emotional side effects.”12(p.301).  
 
Cancer has been described as a “family disease”13 (p.194) which indicates that 
challenges are rarely faced in isolation. Rather, caregivers must adapt. Recognition 
of this has prompted a great deal of research investigating caregivers’ experiences of 
the caring for a loved one with cancer.  During the acute phase of the transplant 
process caregivers report unmet needs such as finding time for themselves and ways 
to deal with the stress they are experiencing14. They also describe feeling responsible 
for their loved one’s care and putting the needs of their loved one before their own3.  
Although this may be necessary during the acute transplant phase, this is likely to 
extend beyond the transplant period if late effects of treatment are experienced and 
may cause a relationship imbalance, and in turn, caregiver distress. Boyle et al.14 
found that “dealing with physical and mental complications” (p.200) post-transplant 
was ranked most difficult by both caregiver and patient.  
 
Equity theory is a useful framework for understanding the experiences of caregivers. 
This theory suggests that within a relationship, individuals strive to maintain a 
balance between what they provide and what they receive. It asserts that inequity in 
either direction causes distress and attempts to restore equity15.  In oncology 
literature, the perception of being under benefitted (either because they provide too 
much for the patient or receive too little) has been linked to higher caregiver 
burden15.  This theory has been supported by results of Langer et al’s.16 study in which 
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caregivers report significant changes to marital dynamics, with approximately 49% 
experiencing decreased marital satisfaction one year following HSCT owing to 
caregiver burden, with female caregivers at greatest risk for decreased satisfaction16. 
 
In the context of distress, Lazurus and Launier (1978) cited by Ogden17 describe 
coping as the process of managing stressors that have been appraised as exceeding 
an individual’s resources.  Coping skills can be categorised into three subtypes, 
appraisal focussed, problem focussed and emotion focussed. Research has indicated 
that  several factors influence strategy selection. These include problem type, 
gender, controllability and resources. Findings from studies examining coping 
strategies in relation to caregiver distress indicate that avoidance coping (whether 
cognitive or behavioural) is consistently associated with higher levels of emotional 
distress18.  Coping is typically thought of as an individual task, however, research has 
demonstrated that couples respond to stressors as units, rather than individuals19. 
One relationship-focussed coping strategy is ‘protective buffering’. This involves 
strategies such as hiding anger, denying worries and avoiding disagreement. Langer 
et al.20 found that increased buffering from caregivers to and from their loved one 
resulted in decreased relationship satisfaction and poorer mental health for both 
parties. 
 
Advances in medicine have improved outcomes for HSCT patients, with more than 
54% of patients surviving one year post-transplant compared to 42% ten years ago21. 
Given the increasing number of cancer survivors who have undergone HSCT, the 
clinical relevance of treatment-related cognitive impairment is considerable. 
Following the transplant, aftercare is provided at home and in 50-91% of the cases, 
the spouse is the primary caregiver18. As a result, the responsibility on the caregiver 
and their requirement to adapt to the changes in their spouse is ever increasing. 
 
A body of research exists exploring patient’s quality of life following HSCT12; the 
experiences of caregivers whose spouses are undergoing HSCT22 or in the acute phase 
of HSCT23. To the author’s knowledge, no study has examined caregivers experiences 
related specifically to the cognitive late effects their spouse has experienced 
following HSCT.  
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AIMS 
The primary aim of this study was to investigate caregivers’ experiences of 
treatment-related cognitive impairment in patients who have undergone a HSCT. 
Secondary aims included gaining an understanding of how the caregivers coped with 
their experiences and what supports they believe could help them. 
 
SUBJECTS AND METHODS 
Ethical considerations 
The research project was assessed and sponsored by the West of Scotland Research 
Ethics Service (WoSRES). Ethical approval was also granted by the Beatson West of 
Scotland Cancer Centre (BWoSCC) Research Ethics Committee. Management 
approval was granted by NHS Greater Glasgow and Clyde Research and Development 
department. Approval for amendments to widen the recruitment procedure was 
granted. This allowed for information packs to be sent to patients who met the 
inclusion criteria but who had attended the Late Effects Clinic within the year prior 
to the study commencing. 
 
Design 
Interpretative Phenomenological Analysis (IPA) has been informed by three key 
philosophies: 1. phenomenology, a philosophical approach to the study of 
experience; 2. hermeneutics, a method of interpretation and 3. idiography, a focus 
on the particular or unique. IPA involves a two-stage process in which the researcher 
aims to explore what personal and social experiences mean to the individuals who 
experience them and to make sense of what the individual is telling us i.e. to make 
interpretations about those experiences24.  IPA is also being increasingly used in 
health psychology research owing to an increasing recognition of the constructed 
nature of illness and therefore, the importance of understanding individuals’ 
perceptions and interpretations of illness25.  For both of these reasons, IPA was 
considered to be the approach most able to address the aims of this study. A semi-
structured topic guide was developed following the guidelines by Smith et al.24.  
Given the scarcity of reports of caregivers’ experiences of cognitive impairment 
following HSCT, the topic guide was modelled on one which explored caregivers 
experiences of the neurocognitive and neurobehavioural changes associated with 
brain tumours26. 
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Sample  
In accordance with IPA methodology, purposive sampling was used. Participants 
(caregivers) were recruited from the Beatson West of Scotland Cancer Centre 
(BWoSCC) Late Effects Clinic. A caregiver was defined as the person who most often 
provides physical and emotional support to the patient. Clinicians working at the 
BWoSCC identified that in most cases, the primary caregiver is a partner or spouse.  
Consultant Haemato-oncologists and a Senior Nurse identified individuals who were 
a caregiver to somebody who: 
 Reports experiencing a degree of cognitive impairment which they 
associate with their Bone Marrow Transplant. Cognitive difficulties 
are identified by using the ‘Patient Distress Thermometer’. (This is 
a self-assessment which alerts clinicians to memory and 
concentration difficulties that the patient is experiencing).  
 Has undergone total body irradiation, high dose chemotherapy or 
a combination of these within the last 20 years. 
 Has no known psychiatric or neurological problems likely to lead to 
cognitive impairments e.g. schizophrenia, previous head injury, 
organic cognitive decline. 
 Has no current use of psychotropic medication. 
 Has no known learning disability. 
 
Participants were excluded from the study if: 
 Their loved one had received total body irradiation, high dose 
chemotherapy or a combination of these within the last year. 
 Their loved one lacked the capacity to consent for their caregiver 
to take part. 
 They did not speak fluent English. 
 
 
Justification of sample size 
IPA is an idiographic approach and therefore has a commitment to detail and depth 
of analysis when attempting to understand a particular phenomenon in a particular 
context. Consequently, the use of small sample sizes when employing IPA is 
recommended. According to Smith et al.24, the typical number of interviews to be 
completed as part of a professional doctorate employing IPA is between four and ten. 
This allows the researcher to gain an in-depth understanding of the individual 
experiences of the participants24. This recommendation is also in keeping with Braun 
and Clarke27 who recommend carrying out enough interviews to demonstrate 
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patterns across a data set, whilst retaining a focus on the experience of individual 
participants. 
 
Recruitment procedure 
Patients who have undergone a Bone Marrow Transplant (BMT) attend the Late 
Effects Clinic annually to identify any difficulties they may be experiencing following 
their cancer treatment. These include physical, emotional, practical, spiritual and  
relationship  difficulties. These are identified using the NHS Greater Glasgow & Clyde 
Haematopoietic Stem Cell Transplantation Services ‘Patient Distress Thermometer’.  
Recruitment took place between February 2016 and June 2016. During this time, if 
any patient attending the Late Effects Clinic identified a memory or concentration 
difficulty, an information pack was given to them. Patients who did not attend the 
Late Effects Clinic between February and June 2016, but were known by the Clinical 
Team to have experienced these symptoms, were also provided with an information 
pack. This contained a cover letter detailing the rationale and aim of the study, 
information sheets for both the patient and their caregiver and a joint consent form 
to be signed by both parties. This ensured that caregivers could not take part without 
their spouse’s permission (Appendices 2.9-2.12).  Participants who returned their 
consent forms were contacted to arrange a suitable time to conduct an interview. 
 
Telephone interviews were offered to all participants as it is recognised that 
caregivers to individuals who have undergone a HSCT have a number of competing 
demands and responsibilities23.  It was acknowledged that telephone interviews may 
result in the loss of non-verbal information which could impact upon rapport. 
Conversely however, it has been suggested that a telephone interview may allow the 
participant to feel more relaxed and comfortable to disclose sensitive information28. 
In addition, as the unrelated allogeneic transplant service serves the whole of 
Scotland, it was hoped that a telephone interview would help facilitate participants 
to take part who lived some distance from Glasgow. Three of five participants chose 
this option.   
 
Interviews took place at the BWoSCC in Glasgow. Participants completed a single 
interview lasting between 30 minutes to 70 minutes (mean 47 minutes). Telephone 
interviews also took place from the BWoSCC.  Interviews were recorded (for 
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telephone interviews via a Sony Electret Condenser Microphone which enabled the 
recording of the conversation onto the digital voice recorder) and transcribed 
verbatim.  To help ensure the validity of the interview guide, the first three interviews 
were anonymised and reviewed by the primary researcher and academic supervisor 
to ensure that they were eliciting data consonant with the aims of the study. The 
topic guide was thought to be appropriate and these three pilot interviews were used 
as part of the data set. The topic guide was used in further interviews without 
modification (Appendix 2.13).   All further interviews were anonymised for references 
to people and places. 
 
 
Data analysis and quality assurance 
Datum were analysed using IPA. The six step process described by Smith et al.24(p.82-
106) was followed. See Appendix 2.16 for a description of the process of data 
analysis. Owing to the subjective nature of qualitative research, it is essential to be 
mindful of factors that are characteristic of high quality qualitative research. 
Yardley’s29 evaluative criteria include sensitivity to context; commitment and rigour, 
transparency and coherence, and impact and importance. See Appendix 2.17 for a 
description of the ways in which the principles of quality assurance were 
demonstrated in the current project. 
 
 
RESULTS 
The central phenomenon was the caregivers’ lived experience of their spouse’s 
cognitive impairment. Four super-ordinate themes emerged from the data: noticing 
change; managing expectations; managing personal feelings and commitment. These 
are shown in Table 1 with corresponding sub-ordinate themes where identified. 
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Table 1. Super-ordinate and sub-ordinate themes 
 
  
NOTICING CHANGE 
Cognitive change 
The quotations below illustrate the insidious onset of their loved ones memory 
impairment or the caregivers increasing recognition of this over time, which initially 
goes unnoticed.  
“It didn’t come until I would say… I didn’t even notice it, it was my 
daughter Lisa that noticed it, like you know, forgetting different 
things twice or three times “I don’t remember where I put the key” 
and that... we went to see Dr eh, Mason,… he didn’t think there 
was anything seriously wrong with him” (Liz, p1, lines 6-10). 
 
“His memory is the main one, him not having a very good memory 
and that’s deteriorated. Well, it wasn’t so,… so obvious at the 
beginning but as we went on, later on, so that’s the main issue” 
(Katie, p1, line 3-6) and “we were really worried, that’s when we 
started looking into it and asking doctors and they said “oh, didn’t 
you know that, yes, that’s a side effect,… obviously he’s thinking 
we already knew that information”(Katie, p2, lines 2-7). 
 
“I mean, he’s definitely more forgetful now, and ehm, he has a 
much shorter fuse, you know? But, at the time, I wasn’t aware of 
that ehm, I suppose” (Paula, p1, line 5-6). 
 
Super-ordinate Themes 
 
Sub-ordinate themes 
Noticing change 
 
 Cognitive change 
 Behavioural change 
Managing expectations 
 
 What will tomorrow bring? 
 An uncertain future 
 Cognitive remediation 
 Maintaining normality 
 Planning for the future 
Managing personal feelings 
 
 Loss  
 Frustration 
 It’s not their fault 
 Nobody knows what it’s like vs. I don’t want 
them to know what it’s like   
 Sharing responsibility 
 Beyond friends and family 
Commitment 
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“His memory now is you know,… quite short. It’s just gradually, he 
would sort of, like if you send him for something, he’ll forget what 
he’s going for sometimes” (Tina, p1, lines 6-7). 
 
Behavioural change 
Although memory difficulties are recognised by caregivers, they also experience 
noticeable changes in their spouse’s behaviour, as a result of cognitive changes. The 
reporting of behavioural changes indicates that the memory problem itself is not the 
only difficulty, or the most salient difficulty for them. 
 
“constantly being told I was wrong and things like that and… ehm, 
never quite coming up to the,… doing enough” (Ange, p2, lines 3-
4) and “he wasn’t as laid back, he was, ehm,… he was kinda of a 
spiky energy” (Ange, p7, line 4).  
 
“he just switches off a lot, you know, he just shuts down now” 
(Tina, p1, line 10) and “if there’s problem’s he’ll go and hide, he 
doesn’t want to know, he cannae deal wae a lot of things or 
anything anymore, or compared to what he used to” (Tina, p2, line 
10). 
 
 “he just wisnae interested, wouldn’t go out, wouldn’t do nothing” 
(Liz, p2, line 2) and “he’s lost a lot of confidence in himself” (Liz, 
p7, line 15). 
 
These changes affect the caregivers in a variety of ways. They include feelings of 
uncertainty regarding what the future holds and personal feelings such as a sense of 
loss and frustration.  
 
MANAGING EXPECTATIONS 
What will tomorrow bring?  
Participants experienced ambiguity about their immediate future owing to what is 
perceived as unpredictable behaviour.  
 
“There’s some mornings I’ve got up and I’ll say to myself, I wonder 
how he’ll be today?” (Liz, p13, line 9). 
 
Although caregivers communicate these changes as unpredictable, from the content 
of their narrative they appear somewhat aware of the mediators of change. In the 
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examples below, the caregivers perceive these “unpredictable” changes as mediated 
by mood or environment.  
 
“it’s unpredictable, there’s no kind of pattern…I find if he’s 
stressed about something as well, he tends to like,… if he knows 
he’s got something coming up, maybe an important thing… or  if 
he’s got time limits on him, he gets more stressed, which then, he 
can’t remember” (Katie, p6, line 9-12). 
 
“When Jake gets up I just wait to see what kinda mood he’s goni 
be in,… if he’s goni maybe speak, or if he’s just goni sit” (Tina, p4, 
line 8-9) and “then other times he could be, be good for a couple 
of weeks and then he’d go back to… it just depends on how he is 
feeling at the time” (Tina, p2, line 8).  
 
 
An uncertain future 
Participants experienced a fear of uncertainty about their future, with regards to 
possible deterioration in their spouse’s cognition and behaviour and the impact it 
may have on their lives. 
 
“it really challenged our relationship” (Ange, p10, line 18) and  “I 
didn’t know if it would survive” (Ange, p11, line 4). 
 
“obviously it was a stressful time and how it affected me was I 
suddenly sort of thought “oh my god, this is terrible” you know, 
I’ve got two sons and I thought I’m going to be the breadwinner, 
I’m going to have to get this sorted out” (Paula, p3, lines  
1-3). 
 
“when we first found out about his memory it was quite upsetting, 
we could hardly speak to each other, both of us were scared, we 
didn’t know if it was goni have a long term effect, like was he goni 
deteriorate?” (Katie, p14, lines 13-16) and “it was a worry because 
we didn’t initially know how bad his memory was goni be, but we 
know that it’s capped and shouldn’t get any worse” (Katie, p8, 
lines 21-22).  
 
Repetition regarding deterioration on two separate occasions indicates that possible 
deterioration was, and perhaps remains a concern. The use of the word “shouldn’t” 
stresses that Katie is aware that no further deterioration is not guaranteed and 
attempts to convince herself of this may be a way of coping with an uncertain future.  
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Caregivers dealt with this uncertainty and fear of deterioration in a number of ways. 
These include attempts to prevent further deterioration by using practical strategies 
to maintain cognitive functioning, attempts to maintain normality and planning for 
the future. 
 
Cognitive remediation 
“I surround him with memory things” (Katie, p1, line 21) and 
“we’ve tried wee games that he can play for his memory” (Katie, 
p5, lines 11-12).  
 
“I put post it’s up and I write everything down for him” (Liz, p6, 
line 24).  
 
Maintaining normality  
“He didn’t want to go out, he wasn’t like that either, he loved a 
night out but he didn’t want to go and I says Robert you can’t do 
this we need to go out” (Liz, p1, lines 16-17). 
 
“so we just talk about our future, what we are going to do, where 
we are going to go, any countries we want to visit, just normal 
future kind of a conversations. We’d like another house,… ehm just 
our future goals and how we are goni get them” (Katie, p8, lines 
22-24). 
 
Planning for the future 
“so I got a full time job because I just knew that we’d have to have 
a way forward, if the worst happened” (Paula, p3, line 4).  
 
“You’ve always got to say, if this goes wrong, this is the plan and 
this is what we are goni do (Katie, p12, lines 22-23) and,…if you 
plan ahead yea, it’s a lot better and less stressful...he knows what 
to expect from me and I know what to expect from him” (Katie, 
p13, lines 1-2).  
 
MANAGING PERSONAL FEELINGS 
Loss 
As a result of the changes in their spouse, caregivers experience a sense of loss. The 
way repetition is used in the examples below, illustrate the severity of change 
(“different” and “totally”) and difficulty accepting this change (“couldnae”). There is 
also a sense that guilt accompanies verbalising these feelings and validation by Tina’s 
daughters may allow her to make this point with more of a clear conscience. The fact 
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that Ange thought her partner had really changed, and therefore asserting a fact, 
rather than a subjective feeling, may have allowed her to feel less guilty for 
expressing this point.  
“he just… couldn’t be bothered with us,… it was, it was total 
personality, just totally changed, he’s like a different different 
different person. It’s hard to explain because I feel as if,... well I’ve 
lost the person that I loved, you know what I mean? He’s just 
totally totally changed,… he just totally,... he’s not the person... 
that I married (Tina, p2, lines 21-24).  
 
“I felt like Norman had really changed at that point, because, ehm, 
I think he had really changed” (Ange, p4, line 22). 
 
 “he’s still very quiet, he’s still very quiet, no the person he was” 
(Liz, p7, line 14) and “at the start, I couldnae, I couldnae,… fae the 
person he was to the person he went to be, I kept saying to myself 
“that’s just no Robert”, you know” (Liz, p9, line 3-4).  
 
As a result of cognitive impairments, caregivers have also experienced a number of 
other losses such as social support and aspirations for the future. This appears as a 
result of spending more time with their loved one in a carer role; the patients social 
isolation owing to a change in affect and an inability to undertake employment owing 
to memory difficulties. 
“when Jake shut down and didn’t want anybody, ehm, to come, I 
lost all my friends (Tina, p4, lines 22-23) and “obviously because 
we never went out anywhere and I was in all the time with Jake” 
(Tina, p5, line 1). 
“so it’s quite stressful because we want to do things in the future 
and there’s only one income coming in at the moment so it’s 
quite….(tails off)” (Katie, p9, lines 19-20) and “financially it’s a bit 
restricting,… it’s a big restriction,…when you are young, you want 
to go out and work, to get a nice house, the things you aspire for 
are just capped, because of the financial constraints of Mike not 
being able to work” (Katie, p13, lines 16-20). 
 
Frustration 
Frustration is a common response to the behaviours displayed as a result of their 
spouse’s limitations. This appears in response to maintaining normality, adjusting to 
their new role and the demands that accompany their spouse’s limitations. 
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“He didn’t want to go out and I says Robert, you can’t do this, we 
need to go out” (Liz, p1, lines 17-18) and “I felt like I was doing 
everything really and Robert wisnae, he wasn’t trying to help 
himself” (Liz, p10, lines 13-14).  
 “Sometimes you want to shake him and try and tell him, 
look, you have to pull your socks up because I need help 
and I’m dealing with everything” (Tina, p3, lines 3-4). 
Frustration or anger appears to be more severe when the caregiver has a belief that 
the limitations or the subsequent behaviours are under their spouse’s control.  
“I do lose the rag wae him,…and he’ll say, “aw Liz, I cannae help 
it”, and I’ll say “you can help it, you’re only going fae here to our 
Kate’s”, “but I just forget” and then he’ll say “I’m sorry” and I’ll say 
“I’m no wanting you to be sorry, I’m just wanting you to keep 
thinking” (Liz, p16, lines 1-4). 
“I’ve said to his face, goni do it for me and the girls, and he just 
looks and says “I’ve tried” (Tina, p7, lines 20-21) and “some people 
can just get up from it and carry on with their life but Jake just isn’t 
one of them” (Tina, p11, lines 1-2). 
 
It’s not their fault 
Caregivers appear to be denying the expression of their own emotions. They  redefine 
their attitudes and behaviours, reminding/convincing themselves that their loved 
one did not choose to be in the position they are (i.e. experiencing cognitive changes 
and in turn, behavioural changes), making their new reality more acceptable.  
“I just tell myself I’ve got to be there for him and I’ve just to,… to 
get myself back on track because at the end of the day, it’s not 
Jake’s fault” (Tina, p5, lines 7-8).  
 “You’ve always got to have in the back of your mind that it’s not 
Mike’s fault” (Katie, p7, line 6) and “you’ve got to hold back and 
go well, there’s reasons behind it” (Katie, p8, lines 4-5).  
 
 
 
Nobody knows what it’s like vs. I don’t want them to know what it’s like  
There is a sense that caregivers feel unheard and not understood and as a result, that 
their needs are not being met. This may be partly attributable to them concealing 
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how they are feeling and therefore others may be unaware of how burdened they 
feel and are less forthcoming with offers of support. 
“Oh I suppose I felt there was a lack of empathy my way, about 
what I was going through as well as what he had gone through” 
(Ange, p4, lines 22-23). 
“It’s alright for you’s, that’s what I say to them, you no wae him 7 
days a week, you know,…you don’t understand…they only see wee 
bits of it , you know” (Liz, p20, line 1-4).  
 
There appears to be a contradiction in terms of perceiving that their own needs 
weren’t getting met and a simultaneous desire not to burden others. 
 “I’ve felt, a lot of times I’ve felt really really down, and I didn’t 
know who to turn to,…I really didn’t know who to turn to coz I 
didn’t want to turn to my daughters coz they’re daddy daft” (Liz, 
p22, lines 13-14) and “most of the time they didn’t know half of 
what I was going through, you know, how I felt, because I didn’t 
tell anybody how I felt”  (Liz, p22, lines 19-20). 
“My girls have been through a lot, I don’t want them to see me 
falling apart because they’ve had a hard time as well,… so…. I’d 
rather deal with it myself” (Tina, p12, lines 3-4). 
 
Sharing responsibility  
Despite not wanting to burden others with their concerns about their spouse,  
advantages are noted  when support is accessed. In addition, those who shared the 
burden of responsibility appeared to be less distressed. 
 “I’ve got great family,… both sides, they’re there for us night and 
day, I just need to lift the phone and there’s someone at my door 
for Robert at anytime” (Liz, p19, lines 5-6).  
“Mike’s family, they’re great too…when I go up into the house I 
don’t need to think as much because he has his family around him 
so we can share the wee bits and bobs and look after him so it’s 
quite good” (Katie, p12, lines 5-8). 
 
While those who hold almost all responsibility for their spouse’s needs appear 
overwhelmed.  
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“Sometimes I feel I could just walk because I feel as if (sighs) I’ve 
had enough at times… but then I say to myself och pull yourself 
together because he needs me… I practically do everything for 
him, and when I go out, he’s standing at the window waiting on 
me coming back” (Tina, p3, lines 18-21).  
 
Caregivers coped with emotional distress independently and by talking with others. 
These examples highlight the divergence in the ways caregivers experienced 
catharsis. The chosen strategy appears to depend on the context and the caregivers’ 
emotional needs at the time. 
“I didn’t cry in front of Robert, but I used to cry up the stairs you 
know” (Liz, p8, lines 11-12) and “believe it or not, I’d say a wee 
prayer” (Liz, p21, line 13).  
“at the time I was designing empathy cards and actually I think 
creating them was a stress release,…all sorts of emotional words 
that I was illustrating” (Ange, p5, lines 19-20) and “I suppose it 
was just a distraction” (Ange, p6, line 2).  
“just being with my friends was a big thing, I mean, I don’t know 
how I would have coped without them (Ange, p6, line 4) and “it 
was just having a sounding board on one level and actually, at 
other times not talking about it at all because you get really,…  you 
kind of need a break from it” (Ange, p6, lines 9-10).  
 “I mean it’s hard sometimes, and it’s emotional but yea, we’re 
just truthful with one another, but sometimes, if it gets intensive 
I’ll just go out with my mum or we’ll chat about things and she 
gives support, or I’ll go out with my brother” (Katie, p13, lines 6-
8).  
 
Beyond friends and family 
Although caregivers adopted a number of strategies to cope with their emotional 
distress, there is a sense that their emotional needs are not fully met by their friends 
and family. Consistently, caregivers reported a wish for someone to talk from the 
beginning of the illness and outwith their family. Despite the profession of that 
person appearing unimportant, there is a sense that they should be a good listener, 
reassuring and be knowledgeable about potential late effects of treatment. 
“it felt as if Norman had amazing care but…there was nobody that 
was constant for all of us” (Ange, p14, lines 15-16) and “I actually 
wanted someone to talk to outside, outside my social group and it 
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wouldn’t have mattered who they were, I literally just wanted to 
kind of say, this is happening, am I going mad? (laughs) or I can’t 
cope” (Ange, p15, lines 4-6).  
“just having someone you can go and speak to,…because it’s not 
Mike you’re frustrated with, it’s the illness he has you’re frustrated 
with,… and (people in the caregivers position) should ask about 
the effects of treatment definitely and what to expect in years to 
come because people could start planning” (Katie, p13, lines 15-
16).  
“see all the medical side for me it was fantastic, but I felt 
emotionally all the time” (Liz, p8, line 11) and “I wish I had 
someone to talk to at times but I wouldn’t have took it to my 
family” (Liz, p23, lines 1-2) and “see fae the day he got home to 
stay home, well I woulda liked a wee group fae then” (Liz, p27, line 
3) and “a group that took to do wae stress and anxiety and feeling 
how you felt” (Liz, p23, lines 7-8).  
 
 
COMMITMENT 
Despite the aforementioned experiences of loss, frustration, uncertainty and 
whether or not they are experiencing the physical intimacy which may be expected 
in romantic relationships, there is a sense of enduring responsibility to their loved 
ones.  A commitment which appears lasting and unyielding.  
“another side is uhm,… physical intimacy, which kind of doesn’t 
happen with somebody who has gone through bone marrow 
transplant for quite a long time,…and that’s quite hard to re-
kindle” (Ange, p11, lines 6-8).  
 “I just wish he would even give me a cuddle or,… sorry” (Tina, p8, 
line 2).  
“when you are in a relationship you just get on with it, it’s just part 
of who he is” (Katie, p3, lines 11-12).  
 “when you are faced with these problems you just have to grit 
your teeth and get on with it” (Paula, p6, line 5).  
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DISCUSSION 
This study sought to explore caregivers’ experiences of their spouse’s treatment-
related cognitive impairment following HSCT. This was achieved by interviewing five 
participants and analysing their transcripts using IPA. Results revealed a gradual 
recognition of cognitive and behavioural change in their spouse which once 
recognised, contributed to feelings of uncertainty, loss and frustration. Caregivers 
employed appraisal, emotion and problem focussed coping strategies to deal with 
their feelings. Despite their distress, caregivers demonstrated an unyielding 
commitment to their spouse.  
 
Although the primary objective of this study was the exploration of treatment-
related cognitive impairment, this symptom appeared to go unnoticed by caregivers 
initially. HSCT is one of the most complex and life threatening cancer treatments. In 
addition to managing the physical difficulties that may accompany HSCT, caregivers 
report uncertainty regarding whether or not their spouse will develop life 
threatening complications and with a 30% mortality rate many years after 
transplantation, uncertainty regarding whether or not their loved one will survive30. 
In the context of the distress induced by these difficulties, their role change and 
increase in caregiving responsibilities, it is unsurprising that this change in cognitive 
functioning initially goes unnoticed.   
 
Caregivers commented on the behavioural changes following treatment. This 
suggests that it is not possible to study one aspect of treatment symptomatology in 
isolation as a result of the far reaching effects of cognitive impairment. It does not 
appear to be the cognitive impairment per se which impacts upon the caregivers 
lives, but the consequences of these cognitive and behavioural changes. There was 
also a sense that caregivers did not know to expect changes which led to feelings of 
uncertainty about the future and efforts to cope with such uncertainty. Previous 
research has indicated that both lack of personal control and lack of preparedness 
increase caregiver distress18. In congruence with these findings, results from the 
current study highlighted that caregivers would value being more informed about 
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potential late effects of treatment, mirroring the result from Jim et al’s.12 exploration 
of patients’ experiences mentioned previously.  
 
In recent years, more research has focussed on the exploration of the moderating 
effects of interpersonal resources within a couple, namely the relationship quality 
between caregiver and receiver in addition to the caregiver’s individual resources31. 
Schumacher et al.31 explored whether caregivers’ perceptions of mutuality in their 
relationship and preparedness for caregiving, moderated the associations between 
perceived difficulty of caregiving and mood disturbance. Results revealed that a good 
relationship between caregiver and patient was insufficient to protect caregivers 
from negative affect. Caregivers also needed to consider themselves well-prepared 
for their caregiving duties. In addition, when both mutuality and preparedness were 
high, mood disturbance did not increase with increasing caregiving demand. Results 
from the current study support these findings. It is clear that participants who seek 
information in an attempt to be prepared and plan for the future and who report 
satisfaction with their relationship appear less distressed by the limitations of their 
spouse, despite high caregiving demands. Conversely, those who infer dissatisfaction 
with their relationship and display a sense of learned helplessness, demonstrating no 
efforts to become more prepared, appear more distressed. However, a number of 
other factors may moderate the relationship between caregiving demand and 
wellbeing. These may include personality characteristics, length of time as a 
caregiver, the caregivers current mental health, age and gender.  
 
As recognition of cognitive and behavioural changes increased, caregivers reported 
frustration at their spouse’s lack of willingness to socialise and help themselves and 
their caregiver, which they found stressful. This illustrates an example of perceived 
inequity in the relationship in which the caregivers perceive being under benefitted, 
which as noted before, leads to higher caregiver burden. Equity theory asserts that 
when in this position, individuals strive to restore equity by altering their inputs, 
leaving the relationship or cognitively distorting inputs and outcomes15. There was a 
consistent sense that caregivers had an enduring commitment to their spouse 
despite their difficulties and therefore leaving the relationship was not considered a 
feasible option.  One possible reason for this may be the context in which caregivers 
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find themselves, having observed their loved one endure a complex and life 
threatening cancer treatment, following which they may feel it is inappropriate to 
strive to restore equity by this means. Rather, caregivers often put their partner’s 
needs before their own, at the expense of their own social interaction and work 
commitments. This has been identified in other explorations of caregiver burden in 
adult cancer populations in which caregivers have reported to modify their lifestyle 
to accommodate the care recipient’s needs, such as reducing their contact with 
friends and family and restricting their leisure activity3. 
 
In order to resolve inequity in the relationship, caregivers adopt a form of appraisal 
coping - accepting the situation by externally attributing their spouse’s difficulties. In 
interpersonal relationships, attributions are used to explain, justify or excuse 
behaviour. Weiner32 asserted that when the cause of requiring help was perceived to 
be external and uncontrollable, others were more likely to respond with sympathy 
and provide help. In line with this theory, caregivers consistently reported instances 
of reminding themselves that the limitations they were frustrated with were not the 
fault of their spouse, or under their control. When the cause of the behaviour is 
perceived to be internal and controllable, others are more likely to respond with 
negative emotions such as anger and less likely to help. In the current study, caregiver 
distress appeared to be higher when they perceived their spouse’s limitations as 
under their control. 
 
All participants illustrated the use of emotion focussed strategies (emotional 
discharge) or problem focussed strategies (seeking information and support).  
However, despite using similar strategies, caregiver outcomes varied considerably. 
For example, all participants used emotional discharge i.e. venting their feelings to 
their partner. For some, this reduced distress, for others this appeared to increase 
distress. In such cases, the outcome appeared not so much dependant on the 
individual coping strategy employed but on the response, or lack thereof, from their 
spouse. In keeping with the literature this highlights the effect of ‘protective 
buffering’ in increasing caregiver distress. It is also possible that outcomes may have 
been moderated by factors suggested by Moos and Schaefer (1984)33. Personal 
factors such as current level of distress, personality, beliefs and previous experiences 
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appeared to affect whether or not caregivers made use of the social support available 
to them. Irrespective of how successful their coping efforts were, there was a 
consensus that additional support would be desirable.  
 
Strengths and limitations 
The use of qualitative methodology is considered a strength as it allowed for an in-
depth exploration of caregivers’ experiences of late effects of HSCT, which to the 
authors knowledge is the first study examining this.  Study limitations include the 
small sample size which consisted of all white Scottish female caregivers, three of 
which were aged between 60-65 (Appendix 2.14).  Although it was felt data 
saturation was reached with the current sample, a more culturally diverse sample 
across the age range may have yielded additional themes. The sample was relatively 
homogenous with the exception of one caregiver aged 35.  The main limitation was 
the response rate. Twelve participants were provided with information packs, 
however, only five participants (42%) consented to take part. There was clear 
divergence in the experiences of caregivers, therefore it is possible that the 
caregivers who took part represent those at the extreme of each end of the 
experience and coping spectrum. Low response rate may also be explained by 
caregivers having a number of other responsibilities perhaps with limited time for 
tasks which will not have any immediate benefits for them.  There is also a possibility 
that the patient population involved provided a barrier to accessing caregivers. There 
was a delay in interviewing two participants as their spouses had forgotten to provide 
them with the information pack. 
 
Clinical implications and future directions 
The current results highlight three potential avenues for clinical application. At 
present patients are given a “next steps” booklet which was written to increase their 
understanding of the long-term recovery and effects of stem cell transplantation. 
However, there is very little information in this booklet about the cognitive late-
effects of treatment. Therefore, supplementing this with a discussion about potential 
cognitive late-effects with patients and their spouses at the pre-discharge stage may 
be helpful. Being more informed might help to reduce the uncertainty spouses report 
and increase their ability to plan for the future. Information about the biological 
causes of such impairment should be included which might help to increase spouses 
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understanding of the lack of controllability of the impairment.  At present, a cognitive 
rehabilitation group is being developed and piloted at the BWoSCC. This will include 
a session for carers which the results of this study will inform.  Secondly, couples 
might benefit from education about the value of emotional expression within the 
relationship. A reduction in protective buffering from both parties may increase 
mutuality in the relationship which, in addition to preparedness mentioned above, 
has been demonstrated to moderate the effects of caregiving demand on mood 
disturbance. Thirdly, spouses reported a desire for someone to provide emotional 
support outwith their family. This is the role of the Clinical Nurse Specialists. It is 
important to ensure that both the patient and their family members know who this 
is, how to contact them and to clarify their role in terms of providing emotional 
support in addition to physical care.  As cancer has been acknowledged as a family 
disease, and caregivers and care recipients are likely to have different needs, future 
research should consider exploring the experiences of couples in order to identify 
any mutual needs, where interventions are likely to create optimum impact. Finally, 
given the current and future focus on health and social care integration, it will be 
important to consider how the needs of patients and their spouses can be met by 
joint working between health, social care and third sector services.   
 
Conclusions 
The results of this study highlight that caregivers adopt a variety of appraisal, 
emotion and problem focussed strategies to deal with feelings of uncertainty, loss 
and frustration owing to the changes identified in their spouse. In keeping with 
previous findings exploring patients’ experiences, caregivers’ highlighted a desire for 
education about late effects of treatment and emotional support outwith the family. 
Meeting these needs would help the caregiver to feel more prepared, which may 
increase their sense of control over their future. Understanding the lack of 
controllability their spouse has over their cognitive and behavioural changes has 
been demonstrated to evoke sympathy and in turn, helping behaviour. Education 
about the role of ‘protective buffering’ may help improve communication of 
emotions within the care dyad. All of these above factors have been demonstrated 
to reduce caregiver burden. 
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Appendix 1.2   Search strategy for Embase 
 
 
1. Bone marrow transplantation/ 
 
2. Hematopoietic stem cell transplantation/ 
 
3. (hematopoietic adj2 transplant*).mp [mp=title, abstract, heading 
word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
 
4. (haematopoietic adj2 transplant*).mp [mp=title, abstract, heading 
word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
 
5. (bone marrow adj2 transplant*).mp [mp=title, abstract, heading 
word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
 
6. Adaptation, psychological 
 
7. Emotional adjustment  
 
8. Coping behaviour  
 
9. Mental stress 
 
10. ((emotional or psychological) adj (wellbeing or coping)).mp 
[mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, 
keyword] 
 
11. 1 OR 2 OR 3 OR 4 OR 5 
 
12. 6 OR 7 OR 8 OR 9 OR 10 
 
13. 11 AND 12 
 
14. Limit 13 to (human and English language and journal and adult 
<18 to 64 years>) 
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Appendix 1.3   Reasons for exclusion at full text level 
 
Reasons for exclusion 
1 - Psychological adjustment not the outcome variable 
2 - No transplant procedures (e.g. chemotherapy only) 
3 - Examining predictors of distress prior to transplant procedure 
4 – Protective/risk factors for adjustment are not psychological e.g. 
demographics/personal changes/medical factors/symptom 
distress/physical limitations) 
Study  Reason 
Baker F, Marcellus D, Zabora J, Polland A, Jodrey D. Psychological Distress 
Among Adult Patient Being Evaluated for Bone Marrow Transplantation. 
Psychosomatics. 1997; 38 (1):10-19. 
3 
Curbow B, Somerfield MR, Baker F, Wingard JR, Legro MW. Personal 
Changes, Dispositional Optimism and Psychological Adjustment to Bone 
Marrow Transplantation. Journal of Behavioural Medicine. 1993; 16 
(5):423-443. 
4 
Frick E, Fegg MJ, Tyroller M, Fischer N, Bumeder I. Patients’ health beliefs 
and coping prior to autologous peripheral stem cell transplantation. 
European Journal of Cancer Care. 2007; 16:156-163.         
3 
Miller DL, Manne SL, Taylor K, Keates J, Dougherty J. Psychological 
Distress and Well-Being in Advanced Cancer: The Effects of Optimism and 
Coping. Journal of Clinical Psychology in Medical Settings. 1996; 3 
(2):115-130. 
2 
Pillay B, Lee SJ, Katona L, Burney S, Avery S. Psychosocial factors 
associated with quality of life in allogenic stem cell transplant patients 
prior to transplant. Psycho-Oncology. 2014; 23:642-649. 
3 
Prieto JM, Blanch J, Atala J, Carreras E, Rovira M, Cirera E, Gasto C. Stem 
cell transplantation: Risk factors for psychiatric morbidity. European 
Journal of Cancer Care. 2006; 42:514-520.  
4 
Rodrigue JR, Boggs SR, Weiner RS, Behen JM. Mood, Coping Style and 
Personality Functioning Among Adult Bone Marrow Transplant 
Candidates. Psychosomatics. 1993; 34 (2):159-164.                 
3 
Rodrigue JR, Pearman TP, Moreb J. Morbidity and Mortality Following  
Bone Marrow Transplantation: Predictive Utility of Pre-BMT Affective 
Functioning, Compliance and Social Support Stability. International 
Journal of Behavioural Medicine. 1999; 6 (3):241-254.                
1 
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   Appendix 1.4   Quality appraisal tool (Downs & Black 1998 Checklist) 
 
All 
criteria 
Description of criteria (with additional explanation if required, determined 
by consensus of raters) 
Possible 
answers 
 
1 Is the hypothesis/aim/objective of the study clearly described? Must be 
explicit. 
Yes/No  
2 Are the main outcomes to be measured clearly described in the 
introduction or Methods section? If the main outcomes are first 
mentioned in the Results section, the question should be answered no. ALL 
primary outcomes should be described for YES. 
Yes/No  
3 Are the characteristics of the patients in the study clearly described? In 
cohort studies and trials, inclusion and/or exclusion criteria should be 
considered. In case-control studies, a case-definition and the source for 
controls should be given. Single case studies must state a source of patient. 
Yes/No  
4 Are the interventions of interest clearly described? Treatments and 
placebo that are to be compared should be clearly described.  
Yes/No X 
5 Are the distributions of principle confounders in each group of subjects to 
be compared clearly described? A list of principle confounders is provided. 
YES= age, severity. 
Yes/No  
6 Are the main findings of the study clearly described? Simple outcome data 
(including dominators and numerators) should be reported for all major 
findings so that the reader can check the major analyses and conclusions. 
Yes/No  
7 Does the study provide estimates of the random variability in the data for 
main outcomes? In normally distributed data, the inter-quartile range of 
results should be reported. In normally distributed data the standard error, 
standard deviation or confidence intervals should be reported. 
Yes/No X 
8 Have all the important adverse events that may be a consequence of the 
interventions been reported? This should be answered yes if the study 
demonstrates that there was a comprehensive attempt to measure adverse 
events (COMPLICATIONS BUT NOT AN INCREASE IN PAIN). 
Yes/No X 
9 Have the characteristics of patients lost to follow-up been described? If 
not explicit = NO. RETROSPECTIVE – if not described = UTD; if not explicit 
re: numbers agreeing to participate = NO. Needs to be >85%  
Yes/No/  
UTD 
 
10 Have actual probability values been reported (e.g. 0.035 rather than 
<0.05) for the main outcomes, except where the probability is less than 
0.001? 
Yes/No  
11 Were the subjects asked to participate in the study representative of the 
entire population from which they were recruited?  The study must 
identify the source population for patients and describe how the patients 
were selected.  
Yes/No/  
UTD 
 
12 Were those subjects who were prepared to participate representative of 
the entire population from which they were recruited? The proportion of 
those asked who agreed should be stated.  
Yes/No/  
UTD 
 
13 Were the staff, places and facilities where the patients were treated, 
representative of the treatment the majority of patients receive? For the 
question to be answered yes the study should demonstrate that the 
intervention was representative of that in use of the source population. 
Must state type of hospital and country for YES. 
Yes/No/  
UTD 
X 
14 Was an attempt made to blind study subjects to the intervention they 
have received? For studies where the patients would have no way of 
knowing which intervention they received, this should be answered yes. 
Retrospective, single group = NO; UTD if>1 group and blinding not explicitly 
stated.  
Yes/No/  
UTD 
X 
15 Was an attempt made to blind those measuring the main outcomes of the 
intervention? Must be explicit. 
Yes/No/  
UTD 
X 
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16 If any of the results of the study were based on “data dredging”, was this 
made clear? Any analyses that had not been planned at the outset of the 
study should be clearly indicated. Retrospective = NO. Prospective = YES.  
Yes/No/  
UTD 
 
17 In trials and cohort studies, do the analyses adjust for different lengths of 
follow up of patients, or in case-control studies, is the time period 
between the intervention and outcome the same for cases and controls? 
Where the follow up was the same for all study patients the answer should 
be yes. Studies where differences in follow up are ignored should be 
answered no. Acceptable range 1 yr follow up=1 month each way; 
months….10 years follow up = 10 months.  
Yes/No/  
UTD 
 
18 Were the statistical tests used to assess the main outcomes appropriate?  
The statistical techniques used must be appropriate to the data. If no tests 
done, but would have been appropriate to do = NO. 
Yes/No/  
UTD 
 
19 Was compliance with the intervention/s reliable? Where there was non 
compliance with the allocated treatment or where there was 
contamination of one group, the question should be answered no. Surgical 
studies will be YES unless procedure not completed.  
Yes/No/  
UTD 
X 
20 Were the main outcome measures used accurate (valid and reliable)? 
Where the outcome measures are clearly described, which refer to other 
work or that demonstrate the outcome measures are accurate = YES. ALL 
primary outcome measures are valid and reliable for YES. 
Yes/No/  
UTD 
 
21 Were the patients in different intervention groups (trials and cohort 
studies) or were the cases and controls recruited from the same 
population? Patients for all comparison groups should be selected from the 
same hospital. The question should be answered UTD for cohort and case 
control studies where there is no information concerning the source of 
patients.  
Yes/No/  
UTD 
 
22 Were study subjects in different interventions group (trials and cohort 
studies) or were the cases and controls recruited from the same 
population? For a study which does not specify the time period over which 
patients were recruited, the questions should be answered UTD. Surgical 
studies must be <10 years for YES, if >10 then NO. 
Yes/No/  
UTD 
 
23 Were study subjects randomised to intervention groups? Studies which 
state that subjects were randomised should be answered yes except where 
method of randomisation would not ensure random allocation. 
Yes/No/  
UTD 
X 
24 Was the randomised intervention assignment concealed from both 
parties and health care staff until recruitment was complete? All 
randomised studies should be answered no. If assignment was concealed 
from patients but not from staff, it should be answered no. 
Yes/No/  
UTD 
X 
25 Was there adequate adjustment for confounding in the analyses from 
which the main findings were drawn? In non-randomised studies if the 
effect of the main confounders was not investigated or no adjustment was 
in the final analysis was made the question should be answered no. If no 
significant difference between groups then YES. 
Yes/No/  
UTD 
 
26 Were losses of patients to follow up taken into account? If the numbers of 
patients lost to follow up are not reported = UTD. 
Yes/No/  
UTD 
 
27 Did the study have sufficient power to detect a clinically important effect 
where the probability value for a difference being due to chance <5%. 
Sample sizes have been calculated to detect a difference of x% and y%. 
1-5  
 
‘X’ indicates the items which were removed for the current systematic 
review. 
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                          Appendix 1.5   Quality ratings of included studies   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Reporting  
/7 
External validity 
/2 
Internal validity 
bias  /4 
Internal validity 
confounding  /4 
Power 
/1 
Overall 
score /18 
Fife et al (2000) 5/7 1/2 4/4 2/4 1/1 13/18 
Goetzman et al (2007) 5/7 1/2 4/4 4/4 1/1 15/18 
Hochhausen et al (2007) 4/7 1/2 4/4 4/4 1/1 14/18 
Jacobson et al (2002) 7/7 1/2 3/4 2/4 1/1 14/18 
Johnson-Vickberg et al (2001) 6/7 2/2 4/4 4/4 1/1 17/18 
Lee et al (2005) 6/7 2/2 2/4 4/4 1/1 15/18 
Rosenberg et al (2015) 5/7 2/2 4/4 4/4 1/1 16/18 
Schumacher et al (2014) 6/7 2/2 4/4 4/4 1/1 17/18 
Warchala et al (2015) 6/7 1/2 3/4 2/4 1/1 13/18 
Wells et al (2009) 7/7 2/2 3/4 3/4 1/1 16/18 
Widows et al (2000)  7/7 2/2 4/4 4/4 1/1 18/18 
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Appendix 1.6   Psychological adjustment outcome measures and associative factors      
                           measures  
 
Outcome measures 
 Bi-polar Profile of Mood States (POMS) 
 SF-36 Health Survey (SF-36) 
 Questions on Life Satisfaction Questionnaire 
 The Centre for Epidemiological Studies of Depression (CES-D) 
 Functional Assessment of Cancer Therapy General (FACT-G) 
 PTSD Checklist – Civilian Version (PCL-C) 
 Brief Symptom Inventory – Global Severity Index (BSI-GSI) 
 Beck Depression Inventory 2nd Edition (BDI-II) 
 Hospital Anxiety and Depression Scale (HADS) 
 Cancer and Treatment Distress measure (CTD) 
 EORTC Quality of Life Questionnaire (EORTC QLQ-C30) 
 General Self-efficacy Scale (GSES) 
 State Trait Anxiety Inventory-State Anxiety Subscale (STAI) 
 Structured Clinical Interview for DSM-IV Axis 1 Disorders:non patient edition  
(SCID-I/NP) 
 
 
Associative factors measures 
 Perceived Family and Perceived Friends Social Support Scale (PFPFSSS) 
 Perceived Health Care Provider Support Scale (PHCPSS)  
 Ways of Coping Checklist (WCC) 
 Mastery Scale 
 Meaning of Illness Scale (MIS) 
 Sense of Coherence Scale Short Version (SOC-13) 
 Life Orientation Test (LOT) 
 Hospital Anxiety and Depression Scale (HADS) 
 Social Support Questionnaire (F-SozU) 
 Rand Medical Outcomes Study Social Support Survey (MOS) 
 Cancer Behaviour Inventory Long Form (CBI-L) 
 Coping Responses Inventory (CRI) 
 Profile of Mood States (POMS) 
 Interpersonal Support Evaluation List Short Form (ISEL-SF) 
 Life Attitude Profile Revised (LAP-R) 
 Beck Depression Inventory 2nd Edition (BDI-II) 
 Hospital Anxiety and Depression Scale (HADS) 
 PTSD Checklist – Civilian Version (PCL-C) 
 Conner Davidson Resilience Scale (CDRS) 
 Acceptance of Illness Scale (AIS) 
 Coutald Emotional Control Scale (CECS) 
 Mental Adjustment to Cancer (MAC) 
 Brief COPE 
 Social Constraint Scale (SCS) 
 Trauma Experience Questionnaire  
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Appendix 2.1   Major research project proposal 
 
ABSTRACT 
Background: For many cancers the treatments involved, such as chemotherapy can be 
physically and psychologically challenging and be associated with lasting adverse 
secondary effects, one of which is cognitive impairment. Common changes occur 
primarily in the domains of executive functioning, processing speed, memory and 
attention. The incidence and severity of this symptom varies widely, however it can 
significantly impact quality of life by interfering with patients’ activities of daily living, 
relationships and future plans. This symptom can also pose challenges for the patients’ 
caregiver, an area which has received comparatively less attention.  
Aims: The aim of this study is to investigate caregivers’ experiences of treatment related 
cognitive impairment in patients who have undergone Haematopoietic Stem Cell 
Transplant (HSCT), how they coped both practically and emotionally and what supports 
they believe could help them   
Methods: Four to ten participants who are a caregiver to an individual who has 
undergone a HSCT in the last 20 years will be recruited via the Beatson West of Scotland 
Cancer Centre (BWoSCC). Each participant will complete an in depth interview exploring 
their experiences which will be analysed using Interpretative Phenomenological Analysis 
(IPA). 
Applications: Given that cognitive compensatory interventions are often enhanced when 
supported by carers, a greater understanding of caregivers’ experiences may provide a 
rationale for the development of a service to meet their needs both psychologically and 
practically and in turn, improve the outcomes of patients undergoing cognitive 
remediation. 
 
INTRODUCTION 
More than one in three people in the UK will develop some form of cancer during their 
lifetime, of which there are more than 200 types, each with different causes, symptoms 
and treatments (Cancer Research UK, 2014). For many cancers, the treatments involved 
can be physically and psychologically challenging and associated with lasting adverse 
secondary effects, such as cognitive impairment (MacMillan Cancer Support, 2013).   
Although the existence and causes of treatment-related cognitive impairment or ‘chemo 
brain’ have been a subject of debate, many studies have confirmed that it is a real, 
measurable side effect of chemotherapy (Evans & Eschiti, 2009). This was first identified 
in the 1980’s when breast cancer patients reported difficulties with cognition during and 
after chemotherapy (van Dam et al. 1998).  Most of the research investigating treatment-
related cognitive impairment has been carried out with breast cancer patients, however 
the exact incidence of its occurrence is unknown owing to the different methods 
employed in the studies such a lack of control group of cancer patients not treated with 
chemotherapy and a lack of baseline measures (van Dam et al. 1998).  At present, it is 
estimated that treatment-related cognitive impairment affects between 17-78% 
(Schagen & Wefel, 2013). 
While physical difficulties may be experienced as transient side effects of cancer 
treatment, for example, increased infection owing to a lowered immunity or day time 
tiredness owing to sleep problems,  some patients continue to experience cognitive 
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difficulties  long after their treatment has ended. For some patients, cognitive 
impairment is present up to twenty years following chemotherapy (Schagen & Wefel, 
2013). Common changes occur primarily in the domains of executive functioning, 
processing speed, memory and attention (Ahles & Saykin, 2001). This is most often seen 
in patients treated for breast, ovarian and prostate cancer in addition to other types of 
cancers requiring high dose chemotherapy such as cancers of the blood or bone marrow.  
Although blood cancers account for only up to 3% of cancer cases, around 26,700 cases 
of the three most common blood cancers (leukemia, lymphoma, and myeloma) are 
diagnosed in the UK every year, 94% of which occur in adults (Cancer Research UK, 2014). 
Haematopoietic Stem Cell Transplant (HSCT) has become the standard treatment for 
certain types of blood or bone marrow cancer and offers the possibility of a cure for 
illness such as multiple myeloma, lymphoma or leukaemia, amongst others. HSCT 
involves the destruction of the recipient’s immune system with high-dose chemotherapy 
and occasionally total body irradiation (tbi), together with immunosuppressant 
medication supported by steroids and anti-rejection drugs in order to eradicate the 
disease prior to the infusion of new stem cells and also to suppress immune reactions 
i.e. graft versus host disease (GvHD), thereby preventing the donor stem cells from 
rejecting the recipients’ body (Cancer Research UK, 2014). 
Bosworth et al,. (2013) carried out a 2 year prospective study of cognitive function 
conducted on 242 HSCT recipients and 98 healthy controls. Participants were asked to 
undergo a two hour battery of standardized neurocognitive tests measuring executive 
function, processing speed, verbal fluency and fine motor dexterity. Participants took 
this test at six, 12 and 24 months after transplant. Owing to a high attrition rate only half 
of the participants remained at the end of the study. Despite the reduction in sample 
size, the researchers found that all four measures of cognitive function were significantly 
worse in HSCT participants. With regards to the duration of symptoms, Syrjala et al., 
(2004) observed significant reductions in neuropsychological test performance between 
their first and second time points, pre HSCT and 80 days respectively, and a general 
recuperation at 1 year post HSCT. Booth-Jones et al., (2005) examined patients 6 months 
after HSCT finding at least mild cognitive deficits in 51% and moderate to severe 
impairment in 28%. 
 
It is difficult to predict which patients will develop treatment-related cognitive 
impairment and for those who do, as evident in the aforementioned studies, duration 
and severity are highly variable. In addition, changes can occur as early as the first 
chemotherapy session and/or accumulate and develop over subsequent treatments. 
Even mild cognitive difficulties can have practical and psychological consequences, 
particularly when persistent or left untreated (Schagen et al., 2014). What is certain is 
that treatment related cognitive dysfunction can significantly impact quality of life by 
interfering with patients’ activities of daily living, interpersonal relationships and future 
plans, this is in addition to a life altering cancer diagnosis. 
 
Advances in medicine have improved patient outcomes after transplantation, with more 
than 54% of patients now alive one year after unrelated donor stem cell transplantation 
compared to 42% ten years ago. Moreover, the increasing ability to transplant older 
patients continues to drive the growing number of transplants in the UK(UK Stem Cell 
Strategic Forum, 2010).  Given the increasing number of cancer survivors who have 
undergone HSCT, the clinical relevance of treatment-related cognitive impairment is 
significant.  
67 
 
 
A few qualitative studies have explored the subjective experiences of treatment-related 
cognitive impairment in cancer patients, however, this is most often amongst breast 
cancer survivors, the most studied group with regards to this symptom. These studies 
have explored quality of life and social reintegration following treatment and have 
attempted to address the needs of patients living with these difficulties. This has 
included increasing education regarding the potential for cognitive changes associated 
with treatment.  
Cancer not only affects the patient but also has a large impact on family members and 
carers and partners who may find that their roles, responsibilities and priorities change 
after their loved one’s cancer diagnosis and throughout treatment and recovery 
(Schubart et al., 2008). Owing to the recognition of this fact, there have been a number 
of studies investigating carers’ experiences of diagnosis, prognosis and the burden of 
care when caring for a loved one with cancer (Doorenbos et al., 2007, XinGao et al., 
2013). Some of the challenges faced include carer sacrifices, monetary losses and poor 
physical and emotional health (Schubart et al., 2008). Comparatively less research has 
investigated caregivers’ experiences specifically of their partner’s cognitive impairment 
and how they coped with their experience. Following their partners treatment, ongoing 
limitations in cognitive functioning and therefore, quality of life pose additional 
challenges for caregivers than those mentioned above, in particular, neurocognitive 
changes that can be difficult to manage (Schubart et al., 2008). 
1.     AIMS 
The aims of this study are to investigate: 
 Caregivers’ experiences of treatment-related cognitive impairment in patients 
(i.e. their loved ones) who have undergone a HSCT. 
 How caregivers coped practically and emotionally. 
 What supports they believe could help them.  
 
2.    PLAN OF INVESTIGATION 
2.1  Participants 
Purposive sampling will be used to recruit individuals via the Beatson West of Scotland 
Cancer Centre (BWoSCC). Consultant Haemato-oncologists will identify individuals who 
are a caregiver to somebody who: 
 Reports experiencing a degree of cognitive impairment which they associate 
with their Bone Marrow Transplant. These difficulties are identified using the 
NHS GG&C Haematopoietic Stem Cell Transplantation Service ‘Patient Distress 
Thermometer’. The Patient Distress Thermometer is already used as part of the 
routine assessment at the Late Effects Clinic and is therefore within the normal 
working remit of the staff.  
 Has undergone total body irradiation, high dose chemotherapy or a 
combination of these within the last 20 years. 
 Has no known psychiatric or neurological problems likely to lead to cognitive 
impairments e.g. schizophrenia, previous head injury, organic cognitive decline. 
 Has no current use of psychotropic medication. 
 Has no known learning disability. 
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Participants will be excluded from the study if: 
 They do not speak fluent English as the interviews will be conducted in English.   
 Their partner has received total body irradiation, high dose chemotherapy or a 
combination of these within the last year. 
 Their loved one lacks the capacity to consent for the caregiver to take part. 
 
2.2  Recruitment Procedures 
Subject to ethical approval and agreement from Consultant Haemato-oncologists and 
Senior Nurses, individuals who are identified as meeting the inclusion criteria and not 
meeting exclusion criteria will be identified by these staff at the Bone Marrow Transplant 
Late Effects outpatient clinic at the BWoSCC.  Patients who have undergone a Bone 
Marrow Transplant attend this clinic annually to identify any difficulties they may be 
experiencing following cancer treatment. These include physical, emotional, practical, 
spiritual and relationship difficulties. These difficulties are identified using the NHS 
Greater Glasgow & Clyde Haematopoietic Stem Cell Transplantation Services ‘Patient 
Distress Thermometer’. 
If the patient identifies a difficulty with their memory/concentration, an information 
pack will be provided to patients. This will contain a cover letter detailing the rationale 
and aim of the study, an information sheet detailing what the study involves and the 
primary researcher’s contact details, should the patient wish to ask any questions prior 
to providing written informed consent and a consent form to allow the patient to 
consent for their caregiver to take part, if they wish to. The patient consent form will 
request confirmation that the patient has had the opportunity to ask any questions 
about the study and is happy for their caregiver to participate. 
The information pack will also contain an information sheet and two consent forms for 
the potential participant. One which requests their permission for the primary 
researcher to contact them to discuss the research further and allow them to ask any 
questions and one which allows them to consent to take part in the study. When patient 
consent and permission to contact the participant consent forms have both been 
received, the primary researcher will contact the caregiver to allow them to ask any 
questions about the study before they decide if they wish to participate, and if so, allow 
an appointment to be made. Written informed consent will be obtained from the 
participant before the interview begins.  The patient themselves will also be informed 
about the currently developing Cognitive Rehabilitation Service at the BWoSCC and 
referred to this service if they wish to be. This service aims to provide patients with 
cognitive rehabilitation techniques to help manage their cancer elated cognitive 
impairment. 
2.3  Measures 
A topic guide will be developed through discussion with the primary researcher and 
supervisors of the project and based on the previous literature. Given the scarcity of 
reports of caregivers’ experiences of cognitive impairment specifically, the topic guide 
will be based on the findings of previous research of caregivers’ experiences of cancer 
symptoms more generally. The aim of the interview is to explore what the participant 
feels is important about their experience, therefore, the topic guide will not constrict 
this exploration of experience, rather the interview will follow the concerns of the 
participant (Smith, Flowers & Larkin, 2009; p.58). 
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2.4  Design 
Interpretative Phenomenological Analysis has been informed by three key philosophies: 
1. phenomenology, a philosophical approach to the study of experience; 2. 
hermeneutics, a method of interpretation; and 3. idiography, a focus on the particular. 
Therefore, the aim of IPA is to explore what personal and social experiences mean to the 
people who experience them and to make sense of what the person is telling us i.e. to 
make interpretations about those experiences (Smith, Flowers & Larkin, 2009; pp.11-39). 
IPA was therefore considered to be the approach most able to address the aim of this 
study. 
2.5 Research procedures 
Pilot interviews will be carried out with a subset of the sample (n=2) prior to data 
collection in order to identify if the topic guide is successful at eliciting data consonant 
with the aims of the study. If not, the topic guide will be modified and a second test of 
the topic guide will be conducted. If no changes are made to the topic guide following 
the pilot interviews, these interviews will be included in the analysis.  The primary 
researcher will conduct interviews for approximately 45-90 minutes with each 
participant using the aforementioned topic guide to guide the interview. All interviews 
will be recorded using a digital voice recorder or for telephone interviews (when a face 
to face interview is not possible), via a device which enables the recording of the 
telephone conversation onto the digital voice recorder. They will then be transcribed 
verbatim by the primary researcher and any identifiers of people or places will be 
removed and  replaced by a pseudonym prior to the second researcher analysing a 
subsample of interviews to ensure that the patient’s identity is concealed.  This recording 
will be stored on a University of Glasgow laptop encrypted with a security application 
accredited to NHS standards. When transcription is completed and checked for accuracy, 
the interview will be transferred onto a compact disc (CD) and retained with other source 
data. Paper documents, such as consent forms and transcribed interviews will be stored 
in a locked filing cabinet in the office of the Chief Investigator of this project, Dr Sarah 
Wilson (Senior Lecturer in Health Psychology, University of Glasgow). The transcripts will  
be analysed using IPA.  
2.6  Data Analysis 
In order to analyse the data, the six step process described by Smith, Flowers and Larkin, 
(2009; pp.82-106) will be followed. Following verbatim transcription of the interviews, 
analysis will involve immersing oneself in the data and noting any recollections of the 
interview experience and initial or striking observations of the transcript. Descriptive, 
linguistic and conceptual noting then begins which allows the researcher to engage with 
the text in detail and begin to analyse the text at an interpretive level. Analysing the 
descriptive, linguistic and conceptual notes will allow the researcher to identify 
emergent themes and when these have been established, consider how these themes 
are connected. This process is then repeated with subsequent transcripts while allowing 
new themes to emerge. The final stage involves identifying themes across cases.  
In the process of IPA, the researcher plays an active role in interpreting the data. It has 
been acknowledged that "inevitably the analysis is a joint product of the participants and 
analyst, the end result is always an account of how the analyst thinks the participant is 
thinking, thus the truth claims of IPA analysis are always tentative and analysis is 
subjective” (Smith, Flowers and Larkin, 2009; p.80). Prior to analysis, the primary 
researcher will practice reflexivity to ensure her perspectives are transparent from the 
outset. In order to reduce any bias in analysis owing to the primary researchers beliefs, 
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a second researcher will analyse a subsample of interviews (n=2) to ensure validity of the 
analysis. 
2.7  Justification of sample size 
IPA is an ideographic approach and therefore has a commitment to detail and depth of 
analysis when attempting to understand a particular phenomena in a particular context. 
Consequently, the use of small sample sizes when employing IPA is recommended. This 
allows the researcher to gain an in-depth understanding of the individual experiences of 
the participants (Smith, Flowers & Larkin, 2009; p.51). In professional doctorates, 
numbers of interviews (rather than number of participants) are typically between four 
and ten. The current study will aim to recruit ten participants, each of whom will be 
interviewed once (Smith, Flowers & Larkin, 2009; p.52). The approximate number of 
patients presenting with cognitive impairment at the Late Effects Clinic each month is 
likely to be  between 6 and 27. This calculation is based on an average of 35 patients 
attending the clinic per month, of which between 17 and 78% may present with cognitive 
impairment (Schagen et al. 2014). 
2.8  Settings and Equipment 
Interviews will be conducted by the primary researcher in a private room at the BWoSCC. 
If this is not convenient for the participant a telephone interview will be arranged. 
Telephone interviews will also be carried out from a private room at the BWoSCC.  After 
receiving permission to contact the participant to discuss the research further, if they 
wish to participate and also wish to be interviewed over the telephone, the participant 
will be asked to sign the consent form from the information pack and return this in the 
freepost envelope provided. When this has been received, the primary researcher will 
contact the participant to arrange a suitable time to meet.  
3.     HEALTH AND SAFETY ISSUES 
3.1  Researcher safety issues 
As the interviews will be conducted on an individual basis, the safety of the primary 
researcher who will be conducting the interview will be ensured by carrying out 
interviews within normal working hours (9am-5pm) at the BWoSCC. This will help ensure 
that staff are nearby should any safety issues arise. No interviews will take place at the 
participants’ home address. 
3.2  Participant safety issues 
Caring for an individual undergoing intensive surgery and consequently suffering from a 
degree of cognitive impairment is likely to be a highly emotive and stressful experience. 
Therefore, before the interview begins, the participant will be informed that they may 
stop the interview at any time. 
If during the interview, the primary researcher identifies any signs of distress or 
psychological difficulties, the interview will be suspended, the participant will be offered 
emotional support and reminded that they can end the interview if they do not wish to 
continue.  If it becomes apparent that there are significant mental health problems, the 
primary researcher will offer a referral to cancer support agencies such as Maggie’s 
Cancer Support Scotland, MacMillan’s support line or the counsellor at the BWoSCC. 
They will also be advised to visit their own GP for assessment and support. 
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4.   ETHICAL ISSUES (including where submissions will be made) 
Ethical approval will be sought from the Research Ethics Committee at the BWoSCC and 
NHS Greater Glasgow and Clyde. Although this study aims to gain an understanding of 
caregivers’ experiences of their loved one’s cognitive impairment, consent will require 
to be sought from the patient themselves to allow their caregiver to discuss the patients’ 
difficulties and how they are being affected by them. Therefore, when Consultant 
Haemato-oncologists and/or Senior Nurses inform the patient of the study, the 
information sheet provided will detail what areas of discussion will be and if they are 
happy to be discussed, invite the patient to invite their caregiver to participate in the 
study. By doing this, the patient themselves will be consenting to allow their caregiver 
to discuss the patients difficulties. This will be demonstrated by ensuring the patient has 
provided written informed consent before any communication is made with their 
caregiver. Please see Section 2.2 - Recruitment procedures. 
 
5.   FINANCIAL ISSUES 
Recording and transcribing equipment will be borrowed from the Mental Health and 
Wellbeing department at the University of Glasgow. Envelopes and postage costs may 
be incurred if the posting of information sheets is not carried out via the BWoSCC. Costs 
will include printing information sheets and consent forms and one telephone pick up 
hands free cable which will be used for telephone interviews. 
      6. TIMETABLE  
    
 
 
 
 
 
 
 
 
 
 
 
7. PRACTICAL APPLICATIONS 
At the BWoSCC a current service development is the support of patients who have 
treatment related cognitive impairment. Given that cognitive compensatory 
interventions are often enhanced when supported by carers, the current study may 
provide a rationale for the development of a service to meet their needs both 
psychologically and practically and in turn, improve the outcomes for patients who are 
undergoing cognitive remediation. 
March 2015 Submit proposal to university 
June/July 2015 Proposal (including all appendices and ethics 
application) assessed 
August/September 2015 Apply for ethical approval from the from the 
Research Ethics Committee at the BWoSCC and 
NHSGG&C 
October 2015-December 
2015 
Recruitment  
January- February 2016 Transcription of interviews (approximately 80 
hours of transcription) 
February-March 2016 Analysis 
April – June 2016 Write up of research 
July 2016 Submit research 
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8. DISSEMINATION OF FINDINGS 
With the patient and participant’s permission, quotations from the interview will be used 
in the final report which will be written up and submitted as partial fulfilment in the 
degree of Doctorate in Clinical Psychology. After completion, the thesis will be held 
within the Glasgow Theses Service which is freely available electronically. Quotations 
and a summary of the findings may also be presented at conferences and published in 
an academic journal. Patients and participants will be offered to receive a summary of 
the study results. 
 
References 
Ahles, T.A. & Saykin, A. (2001). Cognitive effects of standard-dose chemotherapy in 
patients with cancer. Cancer Investigations. 19 (8), 812-820. 
Booth-Jones, M., Jacobsen, P.B., Ransom, S. & Soety, E.  (2005). Characteristics and 
correlates of cognitive functioning following bone marrow transplantation. Bone 
Marrow Transplant. 36, 695-702. 
Bosworth, A. & Bhatia, S. (2013). Reduced-intensity HSCT recipients spared from post-
transplant cognitive impairment. American Society of Haematology (ASH) 58th Annual 
Meeting, presented December 10, 2013. 
 
Cancer Research UK (2014). 
http://publications.cancerresearchuk.org/cancerstats/statsincidence/reporttop10incm
ort.html 
Doorenbos, A.Z., Given, B., Given, C.W., Wyatt, G., Gift, A., Rabber, M., & Jeon, S. 
(2007). The influence of end of life cancer on caregivers. Research in Nursing and 
Health. 30, 270-281. 
Evans, E.K. & Eschiti, V.S. (2009). Cogntive effects of cancer treatment: Chemo brain 
explained. Clinical Journal of Oncology Nursing. 13 (6), 661-666 
Schagen, S.B., Klein, M., Reijneveld, J.C., Brain, E., Deprex, S., Joly, F., Scherwath, A., 
Schrauwen, W. & Wefel, J.S. (2014). Monitoring and optimising cognitive function in 
cancer patients: Present knowledge and future directions. European Journal of Cancer 
Supplement. 12 (1), 29-40. 
Schagen, S.B. & Wefel, J.S. (2013). Chemotherapy related changes in cognitive 
functioning, EJC Supplements. 11, 225-232. 
Schubart, J.R., Kinzie, M.B., & Farace, E. (2008). Caring for the brain tumour patient: 
Family caregiver burden and unmet needs. Neuro-Oncology.10 (1), 61-72.  
Smith, J. A., Flower, P. and Larkin, M. (2009). Interpretative Phenomenological Analysis: 
Theory, Method and Research.London: SagePublications Ltd. 
73 
 
Syrjala, K.L., Dikmen, S.S., Langer, S., Roth-Roemer, S., & Abrams, J. (2004).  
Neuropsychological changes from pre-transplant to one year in patients receiving 
myoblative allogeneic Haematopoetic cell transplant. Blood. 104, 3386-3392. 
The Future of Unrelated Donor Stem Cell Transplantation in the UK. Part 1 Findings and 
Recommendations. A report from the UK Stem Cell Strategic Forum. NHS Blood and 
Transplant. July 2010.   
van Dam, F., Sanne, B., Schagen, S.B., Muller, M.J., Boogerd, W., Wall, E., Fortuyn, D. & 
Rodenhuis, S. (1998). Impairment in cognitive function in women receiving adjuvant 
treatment for high-risk breast cancer: High dose versus standard dose chemotherapy. 
Journal of the National Cancer Institute. 90 (3), 210-218. 
Xin. G., Prigerson, H.G., Diamond, E. L., Baohuo, Z., Wright A.A., Meyer, F. & 
Maciejewski, P. K. (2013). Minor cognitive impairments in cancer patients magnify the 
effect of caregiver preferences in end of life care. Journal of Pain and Symptom 
Management. 45 (4), 650-659. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
74 
 
 
        Appendix 2.2   Guidelines for submission to Bone Marrow Transplantation 
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For full details please visit:  
http://www.nature.com/bmt/bmt_new_gta.pdf 
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              Appendix 2.3 NHS West of Scotland Research Ethics Service (WoSRES) approval 
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   Appendix 2.4   Beatson West of Scotland Cancer Centre (BWoSCC) approval 
 
CTEC approval 
Avril Trevethan 
  
Sent: 09 October 2015 15:18 
To: Gemma Mcgill 
 
 
 
Hi Gemma, 
  
I would like to confirm that your trial below received ‘A’ approval at today’s CTEC 
meeting. Can I clarify your supervisor Chris surname for the minutes. 
  
Title: GMG – Transplant-Caregivers 
Treatment-related cognitive impairment following Haematopoietic Stem Cell  
Transplant:  
Caregivers’ experiences and coping strategies  
 
Good luck with your research. 
  
Kind regards 
Avril 
  
Avril Trevethan 
Regulatory Administrator 
Cancer Research UK Clinical Trials Unit 
(partner in CaCTUS - Cancer Clinical Trials Unit Scotland) West of Scotland  
Beatson Cancer Centre,  
Level 0 
1053 Great Western Road 
Glasgow 
G12 0YN 
  
Tel. No: 0141 301 7176 
 
E-mail address: Avril.Trevethan@glasgow.ac.uk 
Visit our web site at: http://www.crukctuglasgow.org 
The University of Glasgow, charity number SC004401 
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Appendix 2.5     NHS Greater Glasgow and Clyde Research and Development 
                             approval      
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Appendix 2.6   NHS West of Scotland Research Ethics Service (WoSRES) minor      
                                 amendment approval 
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Appendix 2.7    NHS Greater Glasgow and Clyde Research and Development minor    
                                                        amendment approval 
 
Non-substantial Amendment – R&D Ref GN15HA386 Protocol V5 Non-substantial 
Amendment AM01 (22/04/16)  
O’Neill, Elaine [Elaine.O’Neill2@ggc.scot.nhs.uk]  
 
Sent:              18 May 2016 15:04  
                   To:  Gemma Mcgill 
Dear Miss G McGill, 
R&D Ref: GN15HA386    Ethics Ref: 16/WS/0003 
Investigator: Miss Gemma McGill 
Project Title: 'Caregivers experiences and coping strategies relating to patients 
subjective treatment related cognitive impairment following Haematopoetic Stem Cell 
Transplant' 
Protocol Number: V5; 15/01/16 
Amendment: Non-substantial Amendment AM01 (22/04/16) 
Sponsor: NHS Greater Glasgow and Clyde 
I am pleased to inform you that R&D have reviewed the above 
study's Amendment AM01 (22/04/16) and can confirm that Management Approval is 
still valid for this study. 
  
  
Reviewed 
Documents:                                                           
 Version 
  
Dated 
Ethics acknowledgement   06/05/16 
Notice of minor amendment – email   22/04/16 
  
  
I wish you every success with this research project. 
 
Kind regards 
NHS GG&C R&D 
West Glasgow Ambulatory Care Hospital 
Dalnair Street 
Glasgow G3 8SW 
  
Tel: +44 (0)141 232 1815 
Generic email for PR team: RandD.PRTeam@ggc.scot.nhs.uk      
  
Web: www.nhsggc.org.uk/r&d 
  
Please note that R&D operates a paperlite electronic record system. Please submit study documents via email 
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    Appendix 2.8 Letter to recruiters 
 
 
 
 
 
 
 
 
 
 
Dear Colleague,   
 
Re: “Caregivers Experiences and Coping Strategies Relating to Patients Subjective 
Treatment-Related Cognitive Impairment following Haematopoietic Stem Cell 
Transplant” 
 
Thank you for taking the time to read this information sheet. My name is Gemma McGill 
and I am a Trainee Clinical Psychologist at the University of Glasgow. I am currently in 
the initial planning stages of a qualitative research project which aims to investigate 
caregivers’ experiences of treatment related cognitive impairment in patients who have 
undergone Haematopoietic Stem Cell Transplant (HSCT). Given that cognitive 
compensatory interventions are often enhanced when supported by carers, a greater 
understanding of caregivers’ experiences of these challenges will help us to better 
understand their needs and provide appropriate support.  This in turn could improve the 
outcomes of patients undergoing cognitive rehabilitation. 
 
I aim to recruit 10 participants to this research.  These would be the caregivers of patients 
who have received an allogeneic stem cell transplant in NHS GG&C.  The following 
inclusion criteria will apply. 
 
I would be grateful if you could identify individuals who are a caregiver to somebody 
who: 
 
 Reports experiencing a degree of cognitive impairment which they associate with 
their Bone Marrow Transplant. These difficulties are identified using the NHS 
GG&C Haematopoietic Stem Cell Transplantation Service ‘Patient Distress 
Thermometer’. 
 Has undergone total body irradiation, high dose chemotherapy or a combination 
of these within the last 20 years. 
 Has no known psychiatric or neurological problems likely to lead to cognitive 
impairments e.g. schizophrenia, previous head injury, organic cognitive decline. 
 Has no current use of psychotropic medication. 
 Has no known learning disability. 
 
     Participants will be excluded from the study if: 
 They do not speak fluent English as the interviews will be conducted in English.   
 Their loved one has received total body irradiation, high dose chemotherapy or 
a combination of these within the last year. 
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 Their loved one lacks capacity to consent for their caregiver to take part.  
 
Subject to your agreement, I will ask you to identify individuals who meet the inclusion 
criteria and who do not meet the exclusion criteria at the Bone Marrow Transplant Late 
Effects Clinic at the BWoSCC.  If the patient identifies a difficulty with their 
memory/concentration, I will ask you to provide the patient with an information pack. 
This will include a covering letter, information sheets for the patient and their caregiver 
detailing the rationale, the aim of the study and what would be required of the caregiver 
e.g. areas of discussion should the patient consent and invite their caregiver to 
participate, and a consent form.  
 
Please find enclosed the documents referred to above. I would be grateful if you could 
let me know if this recruitment procedure sounds feasible and if you are able to help. 
Thank you in advance for your time.  
 
Please do not hesitate to contact me at g.mcgill.1@research.gla.ac.uk  or Dr Christopher 
Hewitt at christopher.hewitt@ggc.scot.nhs.uk if you have any questions about this 
research. 
 
Yours sincerely, 
 
 
 
Gemma McGill 
Trainee Clinical Psychologist 
 
 
Under supervision of  
 
 
Dr Christopher Hewitt (Consultant Clinical Psychologist, BWoSCC) 
Dr Sarah Wilson (Senior Lecturer in Health Psychology, University of Glasgow) 
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Appendix 2.9     Cover letter to patient 
 
 
 
 
 
 
 
 
                     
 “Caregivers Experiences and Coping Strategies Relating to Patients Subjective 
Treatment-Related Cognitive Impairment following Haematopoietic Stem Cell 
Transplant” 
 
Dear……………………. 
 
Thank you for taking the time to read this letter. My name is Gemma McGill and I am a 
Trainee Clinical Psychologist studying at the University of Glasgow. I understand that the 
symptoms you might experience following cancer treatment (such as difficulties with 
your memory and concentration) can impact upon your day to day activities and quality 
of life. In addition, I understand that these symptoms may not only affect the individual 
who has had the illness, but also family members and caregivers, amongst others. I am 
interested in finding out more about caregivers’ experiences of the symptoms you may 
be experiencing following your cancer treatment, and how they have coped with these 
experiences.  
 
Please find enclosed an information sheet which tells you more about this research 
project. If you are happy for your caregiver to be offered the opportunity to take part in 
this research, please provide them with the information sheet titled “Participant 
information sheet.” If your caregiver is interested in taking part in this project, I would 
be grateful if you both could complete the “Patient and Participant” consent form, and 
return this to me at your earliest convenience, in the stamped addressed envelope 
provided.  
 
If you would like more information beyond what is provided in the enclosed 
information sheets, please do not hesitate to contact me on 07854 454 691 or at 
g.mcgill.1@research.gla.ac.uk 
 
Thank you for your time. 
 
Yours sincerely, 
 
Gemma McGill 
(Trainee Clinical Psychologist) 
 
Under supervision of  
Dr Christopher Hewitt 
(Consultant Clinical Psychologist, Beatson West of Scotland Cancer Centre)  
 
Dr Sarah Wilson 
(Senior Lecturer in Health Psychology, University of Glasgow) 
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Appendix 2.10   Patient information sheet 
 
   
Patient Information sheet 
 
 “Caregivers Experiences and Coping Strategies Relating to Patients Subjective 
Treatment-Related Cognitive Impairment following Haematopoietic Stem Cell 
Transplant” 
 
Thank you for taking the time to read this information sheet. Being provided with this 
information sheet means that your caregiver is eligible to take part in this research. 
Before you decide if you would like to invite your caregiver to take part, it is important 
that you understand why this study is being carried out and what it will involve.   
 
Why is my caregiver being asked to participate? 
My name is Gemma McGill and I am a Trainee Clinical Psychologist studying at the 
University of Glasgow. I am interested in finding out more about caregivers’ experiences 
of their loved one’s cognitive difficulties, such as difficulties with memory, concentration 
and planning, amongst others, following cancer treatment. This is because we know that 
cancer and its treatment not only affects the individual who has had the illness, but also 
family members and caregivers. Ongoing difficulties in cognitive functioning can pose 
challenges for caregivers and I am interested in learning more about these experiences.  
 
Does my caregiver have to take part? 
No, your caregiver’s participation is voluntary and would require your consent. 
 
What would the interview involve? 
Following receipt of both your, and your caregivers consent, I would arrange a time that 
is convenient to talk to your caregiver. This would take place at the Beatson West of 
Scotland Cancer Centre (BWoSCC) or if that was not convenient, over the telephone. The 
interview would last between 45-90 minutes.  The aim of the interview is to explore your 
caregiver’s experiences with regard to any cognitive symptoms you have experienced 
following your cancer treatment; how they have coped with these both practically and 
emotionally and what supports they think may be helpful to them. The interview would 
be recorded which would allow me to have an accurate record of our discussion.  
 
What are the advantages of taking part? 
There are no direct or immediate benefits for you if you decide to consent for your 
caregiver to take part. However, what we learn from your caregivers’ experiences would 
help to inform how services might better meet the needs of caregivers in the future. In 
addition, strategies which are sometimes given to patients to help with cognitive 
difficulties are often enhanced when supported by input from caregivers. Therefore, a 
better understanding of caregivers’ needs in relation to the cognitive difficulties you are 
experiencing may improve the outcomes for other individuals with similar difficulties. 
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Will I or my caregiver be paid for taking part? 
No payment will be made for taking part. 
 
What are the disadvantages of taking part? 
There are no direct disadvantages for you if you decide to consent for your caregiver to 
take part. However, it is possible that the interview may cover topics that your caregiver 
may find difficult to talk about, depending on their experiences. They will be informed 
that they may end the interview at any time. If they wish to continue, regular breaks will 
be offered. They will also be signposted to appropriate sources of support if they think 
they would benefit from this, or be advised to contact their own GP. 
 
Who will know my caregiver is taking part? 
The staff at the Bone Marrow Transplant Late Effects Clinic will know that your caregiver 
is eligible to take part in the study and therefore, will have provided you with this 
information sheet. However, they will not know if you provided consent for your 
caregiver to take part. Therefore, nobody involved in your care will know your caregiver 
is taking part. The information your caregiver provides will be confidential, unless 
something is revealed during the discussion which indicated that you, your caregiver, or 
someone else is at risk of harm. In that situation, I have a duty of care to share this 
information with the appropriate professionals, but I would tell your caregiver before I 
did this.  
 
What will happen to the information my caregiver and I provide? 
The interview will be recorded which will allow me to have an accurate record of the 
discussion between your caregiver and I.  The recording will be stored on a password 
protected computer which only I have access to. Following the interview, the recording 
will be typed up and any information that identifies people or places will be removed 
and replaced so that neither you nor your caregiver can be identified. A sample of typed 
up interviews will be read by my supervisors; however, this will be following the removal 
of any identifiable information, so they will not be able to identify you or your caregiver. 
The recorded interview will be transferred onto a compact disc (CD) and stored securely 
along with your signed consent form, in a locked filing cabinet in the office of the Chief 
Investigator of this project, Dr Sarah Wilson (Senior Lecturer in Health Psychology, 
University of Glasgow). The recording will then be deleted from the computer. 
Representatives of the study Sponsor, NHS GG&C may look at your personal information 
to make sure that the study is being conducted properly.  
 
What will happen to the results of the study? 
With your permission, we may want to use quotations from your caregiver’s interview 
in the final report which will be written up and submitted as part of my academic work 
for my degree in Doctorate in Clinical Psychology. The quotations may also be presented 
at conferences and published in academic journals.  As mentioned previously, all 
information that could identify you or your caregiver will have been removed. You will 
be provided with a summary of the results if you wish, and access to the full report will 
be available electronically via the University of Glasgow Theses Service.  
 
 
Who has reviewed this study? 
This study has been reviewed by academic staff from the Doctorate in Clinical Psychology 
at the University of Glasgow. It has also been reviewed by a Research Ethics Committee 
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which exists to protect your interests, and the Research and Development department 
of NHS Greater Glasgow and Clyde. 
 
Independent Advisor for further information 
If you are undecided about inviting your caregiver to take part and would like to speak 
to someone who is not directly involved in this study but who is aware of what the study 
involves, please contact Dr Hamish McLeod, (Programme Director for Doctorate in 
Clinical Psychology and Senior Lecturer at the Institute of Mental Health and Wellbeing).  
You can contact Dr McLeod on 0141 211 3920 or email him at 
Hamish.McLeod@glasgow.ac.uk 
 
I am happy for my caregiver to participate, what should I do? 
I would kindly ask that you give them the enclosed information sheet titled “Participant 
information sheet.” If your caregiver is interested in taking part in this project, I would 
be grateful if you could both complete the “Patient and Participant” consent form, and 
return this to me at your earliest convenience, in the stamped addressed envelope 
provided. This confirms that you have both read and understood the information 
provided to you, that you have had the opportunity to ask any questions about the study, 
and that you are happy for your caregiver to participate. Due to the design of the study, 
a maximum of 10 caregivers will be interviewed, and therefore, recruitment will be on a 
first-come, first-served basis.  
 
If you would like more information beyond what is provided in the enclosed information 
sheet or to discuss this project further, please do not hesitate to contact me on 07854 
454 691 or at g.mcgill.1@research.gla.ac.uk 
 
Thank you for your time.  
 
 
 
Sincerely,  
 
Gemma McGill 
(Trainee Clinical Psychologist) 
 
Under supervision of  
 
Dr Christopher Hewitt (Consultant Clinical Psychologist, BWoSCC) 
Dr Sarah Wilson (Senior Lecturer in Health Psychology, University of Glasgow) 
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Appendix 2.11  Participant information sheet 
 
 
 
 
 
 
 
        Participant Information sheet 
 
 
“Caregivers Experiences and Coping Strategies Relating to Patients Subjective 
Treatment-Related Cognitive Impairment following Haematopoietic Stem Cell 
Transplant” 
 
Thank you for taking the time to read this information sheet. Being provided with this 
information sheet means that you are eligible to take part in this research if your loved 
one provides their consent.  Before you decide if you would like participate it is important 
that you understand why this study is being carried out and what it will involve.   
 
Why am I being asked to participate? 
My name is Gemma McGill and I am a Trainee Clinical Psychologist studying at the 
University of Glasgow. I am interested in finding out more about caregivers’ experiences 
of their loved one’s cognitive difficulties. These include poor memory, concentration and 
planning, amongst others, following cancer treatment. We know that cancer and its 
treatment not only affects the individual who has had the illness, but also family 
members and caregivers.  Ongoing cognitive difficulties can pose challenges for 
caregivers and I am interested in learning more about these experiences.   
 
Do I have to take part? 
No, participation is voluntary. If you did decide to take part, you are free to withdraw 
from the study at any time. It will not affect the medical care your loved one receives if 
you decide not to take part or if you withdraw from the study after you have agreed to 
take part.  
 
What would the interview involve? 
Following receipt of both your, and your loved one’s consent, I would arrange a time that 
is convenient to talk to you. This would take place at the Beatson West of Scotland 
Cancer Centre (BWoSCC) or if that was not convenient, over the telephone. The 
interview would last between 45-90 minutes.  The aim of the interview is to explore your 
experiences with regard to any cognitive symptoms your loved one has experienced 
following their cancer treatment; how you have coped with these experiences both 
practically and emotionally and what supports you think would help you. The interview 
would be recorded which would allow me to have an accurate record of our discussion.  
 
What are the advantages of taking part? 
There are no direct or immediate benefits for you if you decide to take part. However, 
what we learn from your experiences will help us to understand how services might 
better meet the needs of caregivers in the future. In addition, strategies which can be 
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given to patients to help with cognitive difficulties are often enhanced when supported 
by caregivers. Therefore, a service which helps caregivers to better understand or cope 
with the cognitive difficulties their loved ones are experiencing may, in turn, improve the 
outcomes for the individuals engaged in rehabilitation for these difficulties. 
 
Will I or my loved one be paid for taking part? 
No payment will be made for taking part. 
 
What are the disadvantages of taking part? 
You may have found that caring for an individual with cognitive difficulties is a 
challenging experience. It is possible that the interview may cover topics that you may 
find difficult to talk about. If this is the case, you may stop the interview at any time.  If 
you wish to continue, regular breaks will be offered. You will also be directed to sources 
of support if you think you would benefit from this.   
 
Who will know I am taking part? 
The staff at the Bone Marrow Transplant Late Effects Clinic will know that you are eligible 
to take part in the study and will have provided your loved one with an information pack. 
However, they will not know if your loved one provided their consent for you to be 
invited to participate and therefore will not know if you are taking part.  The information 
you provide will be confidential, unless something is revealed during the discussion 
which indicated that you, your loved one or someone else is at risk of harm. In that 
situation, I have a duty of care to share this information with the appropriate 
professionals, but I would tell you before I did this.  
 
What will happen to the information I provide? 
The interview will be recorded which will allow me to have an accurate record of our 
discussion. The recording will be stored on a password protected computer which only I 
have access to. Following the interview, the recording will be typed up and any 
information that identifies people or places will be removed and replaced so that neither 
you nor your loved one can be identified.  A sample of typed up interviews will be read 
by my supervisors; however, this will be following the removal of any identifiable 
information, so they will not be able to identify you or your loved one. The recorded 
interview will be transferred onto a compact disc (CD) and stored securely along with 
your signed consent form, in a locked filing cabinet in the office of the Chief Investigator 
of this project, Dr Sarah Wilson (Senior Lecturer in Health Psychology, University of 
Glasgow). The recording will then be deleted from the computer. Representatives of the 
study Sponsor, NHS GG&C may look at your personal information to make sure that the 
study is being conducted properly.  
 
What will happen to the results of the study? 
With your permission, we may want to use quotations from your interview in the final 
report which will be written up and submitted as part of my academic work for my 
degree in Doctorate in Clinical Psychology. The quotations may also be presented at 
conferences and published in academic journals. As mentioned previously, all 
information that could identify you or your loved one will have been removed. You will 
be provided with a summary of the results if you wish, and access to the full report will 
be available electronically via the University of Glasgow Theses Service.  
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Who has reviewed this study? 
This study has been reviewed by academic staff from the Doctorate in Clinical Psychology 
at the University of Glasgow. It has also been reviewed by a Research Ethics Committee 
which exists to protect your interests, and the Research and Development department 
of NHS Greater Glasgow and Clyde. 
 
Independent Advisor for further information 
If you are undecided about taking part and would like to speak to someone who is not 
directly involved in this study but who is aware of what the study involves, please contact 
Dr Hamish McLeod, (Programme Director for Doctorate in Clinical Psychology and Senior 
Lecturer at the Institute of Mental Health and Wellbeing).  You can contact Dr McLeod 
on 0141 211 3920 or email him at Hamish.McLeod@glasgow.ac.uk 
 
I think I would like to participate, what should I do? 
If you would like to participate I would ask that you kindly complete the “Patient and 
Participant Consent Form”, and return this to me at your earliest convenience, in the 
stamped addressed envelope provided. This confirms that you have both read and 
understood the information provided to you, that you have had the opportunity to ask 
any questions and that you are willing to take part.  
I would be grateful if you could provide your contact details on page 3 of the “Patient 
and Participant Consent Form.” This will allow me to contact you to arrange a suitable 
time for the interview.  
 
Due to the design of the study, a maximum of 10 caregivers will be interviewed, and 
therefore, recruitment will be on a first-come, first-served basis. If 10 other caregivers 
have already expressed an interest when I receive your consent form, I will contact you 
to let you know. If you still wish to take part, you will be invited to join a waiting list in 
case any other caregivers decide that they no longer wish to take part.  
 
If you would like more information beyond what is provided in the enclosed information 
sheet or to discuss this project further, please do not hesitate to contact me on 07854 
454 691 or  at g.mcgill.1@research.gla.ac.uk 
 
 
 
Thank you for your time. 
 
 
Sincerely,  
 
Gemma McGill 
(Trainee Clinical Psychologist) 
 
Under supervision of  
 
Dr Christopher Hewitt (Consultant Clinical Psychologist, BWoSCC) 
Dr Sarah Wilson (Senior Lecturer in Health Psychology, University of Glasgow) 
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Appendix 2.12   Joint patient and participant consent form 
 
 
 
 
 
 
 
 Patient and Participant Consent form 
 
“Caregivers Experiences and Coping Strategies Relating to Patients Subjective 
Treatment-Related Cognitive Impairment following Haematopoietic Stem Cell 
Transplant” 
 
I would be grateful if the patient who attends the Bone Marrow Transplant Late 
Effects Clinic could please complete page 1 and 2 of this consent form.                                                                                                                                                       
 
                                                                                                                                          Please initial box 
I confirm that I have read and understood the information provided in                  
the patient information sheet (Version 4, 3.2.16) for the above study. 
 
I confirm that I have had the opportunity to ask questions before inviting  
my caregiver to participate in the above study. 
 
I understand that my caregiver’s participation is voluntary and their  
decision to withdraw from the study at any time will not affect my  
medical treatment in any way. 
 
I understand that the interview will be recorded, kept confidential and  
stored securely within the University of Glasgow until it is  destroyed in line  
with University of Glasgow and NHS Greater Glasgow and Clyde procedures.  
 
I understand that anonymised quotations from my caregiver’s interview may be 
used in the final report written as part of the researcher’s academic work for the 
degree in Doctorate in Clinical Psychology and presented at conferences, published 
in academic journals and be accessed via the Universityof Glasgow Theses Service. 
 
I consent for my caregiver to take part in this study if they wish to.  
 
I consent for my caregiver to disclose my age and gender if they feel it is  
necessary for the explanation of issues. 
 
I would like to receive a written summary of the results when the study has been  
completed (Please provide your contact details overleaf.)   
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Please insert posting address: 
 
………………………………………………………………………………………………………………………………… 
 
………………………………………….….……………………………….……………………………………………… 
 
 
Or emailed to me at the following email address, (please insert email address).  
 
………………………………………………………………………………………………………………………………… 
 
 
 
 
______________________       ______________________          ________________ 
Name of patient                                        Signature                                       Date 
 
 
 
 
_____________________         ______________________       __________________ 
Name of researcher                                 Signature                                       Date 
(To be completed by primary researcher following receipt of patient and participant 
consent.) 
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I would be grateful if the caregiver could please complete page 3 and 4 of this 
consent form. 
 
 
Please initial box  
I confirm that I have read and understood the information provided in  
the participant information sheet (Version 4, 3.2.16) for the above study. 
 
I confirm that I have had the opportunity to ask questions about the above study 
before providing my consent to participate. 
 
I understand that my participation is voluntary and that my decision to withdraw  
from the study at any time will not affect my loved one’s medical treatment  
in any way. 
 
I understand that the interview will be recorded, kept confidential and  
stored securely within the University of Glasgow until it is  destroyed in line  
with University of Glasgow and NHS Greater Glasgow and Clyde procedures.  
 
I understand that anonymised quotations from my interview may be used in the 
final report written as part of the researcher’s academic work for the degree in  
Doctorate in Clinical Psychology and presented at conferences, published in  
academic journals and be accessed via the Universityof Glasgow Theses Service. 
 
I consent to take part in this study. 
 
 
I would like to receive a written summary of the results when the study has been  
Completed. Please provide your contact details below.  
 
Please insert posting address: 
 
………………………………………………………………………………………………………………………………… 
 
………………………………………….….……………………………….……………………………………………… 
 
Or emailed to me at the following email address, (please insert email address).  
 
……………………………………………………………………………………………………………………………… 
 
 
Home phone number:  ……………………………. 
 
Mobile phone number: ……………………………. 
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___________________________        ______________________          ___________ 
Name of participant (caregiver)            Signature                                       Date 
 
 
 
___________________________         ______________________       ____________ 
Name of researcher                                 Signature                                       Date 
(To be completed by primary researcher following receipt of patient and participant 
consent). 
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 Appendix 2.13   Topic guide for interview 
 
1 What do you and your partner/loved one call the difficulties they are experiencing? 
 
2 Can you tell me about when you first realised/noticed  your (partner/loved one) was 
having some difficulties with their (insert their choice of term, e.g. memory) 
    Prompts: - When was this? (try to determine how recently after treatment) 
                      -What was happening around that time for you and your loved one  
                        (to determine levels of stress 
                     -How were you feeling at that time? 
3 Can you describe the difficulties they had/have?  
       Prompts: What difficulties did you/partner notice: Memory 
                                                                    Attention 
                                                                    Concentration 
                                                                    Planning 
                                                                    Multi-tasking 
4 What did you think was causing this? 
        Prompts: Did you know to expect this? 
                         How did you know to expect this? (who told you?) 
                         How did that make you feel? 
5 What were/are the implications of these difficulties?  
        Prompts: Has there been any effect on your relationship?  
                         Roles/responsibilities 
                         Stress levels / your own health 
                         Work 
                         Leisure time / home life 
                         Future plans 
                         What has been the best/worst aspect of your situation? 
6 How do you cope/manage these difficulties emotionally? How have you 
coped/managed? 
       Prompts: What helps/doesn’t help?  
7 How do you/have you coped/managed these difficulties practically?  
       Prompts:  What helps / doesn’t help? 
8 Has there been any change in the symptoms or symptom severity over time?  
       Prompts: Improved/declined – what effect has that had on you? 
                         Do you expect a change? 
                         How do you feel about that? 
9 Is there anything you wish you had known about the cognitive impairment before 
your experiences? 
        Prompt: Would that have made a difference to: Relationships 
                                                                                               Stress 
                                                                                               Health  
                                                                                               Work etc (as in question 5)                                                             
10 Would anything have made your experience easier to cope with?  
        Prompt: Do you feel there are services available to support you? 
                        Yes: What are they? In what ways are they helpful/unhelpful? 
                        No: Has anyone informed you of them?  
11 When would this support have been most helpful? 
12 What advice would you give to someone in a similar situation to yourself? 
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     Appendix 2.14   Participant demographics 
 
Participant 
no.  
Participant 
gender 
Participant 
age 
Patient 
gender 
Patient age 
1 Liz Female 65 Male 64 
2 Ange Female 51 Male  54 
3 Katie Female 35 Male  34 
4 Paula Female 64 Male 70 
5 Tina Female 60 Male 61 
 
 
98 
 
 
 
Appendix 2.15  Excerpts from interviews 3 and 5 
 
 
Emergent themes Original transcript - Katie Exploratory comments  
 
His needs first. 
 
Limitations cause 
frustration. 
 
 
 
Compensating for his 
limitations. 
 
 
 
 
 
 
 
 
 
 
 
Commitment to 
partner. 
Acceptance, (easier to 
accept as he hasn’t 
caused this problem) 
P: yea, its,… its stressful,… it can be stressful because when I’m at work 
and I’m in the middle of, my work can be really intensive and I’m maybe in 
the middle of a situation and I know that Mike has a hospital appointment 
or he has the dog, the dog has an appointment or something,…. I’ve got to 
ensure that I’ve either set my alarm or set his alarm for him to take his 
medication or for him to take it on time because he forgets quite easily. 
He forgets they things and then he forgets he’s got to go and do 
something or he’s got to go to his mums for something or whatever it may 
be so I find that yea, when I’m in the middle of doing something at my 
work I’ve got to take time out to remember or on Mike’s behalf to contact 
him to let him know, but ehm,… we work really well, we work well 
together. It’s not something that I’ve actually sat down and thought about 
until ehm, you’ve asked me the questions, because I think you just,… 
when you’re in a relationship you just get on with it, it’s just part of who 
he is and who I am, so together as a team 
 
 
I: aw how lucky for Mike that he’s got someone so supportive. I mean it 
sounds like it does really affect you but you’ve got a sense of well, that’s 
him, we’re a team, I just need to sort of get on with things? 
 
P:  yep, make it as easy for him as I can, because it’s not something that he 
would have wanted or something that he’s wished for but it’s something 
that we need to work through, that’s just, yea. 
 
 
 Out of the blue that work is intensive, suggests 
Mike’s limitations make an already stressful 
situation more stressful. Can’t simply focus on 
work at work times. Always thinking of Mike. 
 
Repetition of forgets suggests this is the main 
problem. 
 
“whatever it might be” suggests he is forgetting a 
variety  of things.  
 
Repetition, confirming they work well together 
OR attempts to convince self they work well 
together? 
Helping is obvious/second nature. 
Belief that if you have committed to someone 
you deal with their difficulties regardless of the 
stress it creates. 
 
 
 
He didn’t ask for this limitation 
 
Sympathy for Mike causes her to put his needs 
before her own, despite the stress it causes 
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Emergent themes Original transcript - Tina Exploratory comments  
 
 
Hopeless, nothing can 
improve the situation. 
 
Learned helplessness. 
 
 
 
 
Commitment despite 
distress. 
 
 
some people can get up from it and then just carry on with their life, but 
Jake is just not one of them that can deal with anything 
I: so the fact that he sort of struggles to cope, that sort of really impacts 
on you by the sounds of it because you then have to pick up everything 
P: yep, yep 
I: and, has there been anything that you think might have made these 
experiences easier to cope with? Have you received any support? 
P: no, no. 
I: is there anything you think might have been helpful? Say you went to 
someone now, and said these are all the problems I’m having and have 
had for the past 10/15 years, what sort of support would you think might 
be helpful, what would make a difference? 
I: just for my life to go back to where it was at the beginning, (pause), I 
mean that is the only thing because, as much as I say I’d love to get up and 
walk away, I love him and I could never leave him 
 
Resent that they are the unlucky ones who can’t 
deal with anything, that can’t carry on as normal 
despite difficulties. 
‘anything’ highlights the severity of lack of coping  
Repetition suggest a strong sense of agreement 
with summary given by interviewer 
 
Shut down to idea of possible support/help. 
Perhaps as a result of feeling this way for so long. 
Does not believe anything will help. Repetition 
suggest this is a strongly held belief 
 
Loyalty over-rides difficulties. 
No life other than pre-transplant will do. Sense of 
conflict between meeting her needs and meeting 
partners. Pause highlights contemplation, a there 
is a sense she is remembering the past. Love and 
commitment prevents her from leaving 
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Appendix 2.16   Process of Analysis  
  
Smith et al’s (2009) 
six step process of 
analysis 
Process engaged in by researcher 
Reading and re-
reading 
Transcripts were read and re-read, allowing the researcher to 
become immersed in, and actively engaged with the data.  
Initial noting Original transcript data was copied into a 3 column table.  
Initial noting of anything of interest was completed in 1 
column. This included anything that appeared emotive for the 
participant, anything that was repeated, use of language such 
as laugher, pauses,  any contradictions, etc. 
Developing emergent 
themes 
Using the initial notes, provisional emerging themes were 
noted in another column which sought to combine the 
participants original words and thoughts and the researchers 
interpretation of the words and thoughts. 
Searching for 
connections across 
emergent themes 
Emerging themes were written on post-its and placed on a 
large table to allow the researcher to explore spatial 
representations of how the emerging themes best fitted 
together.  
Moving on to the next 
case 
The above process was repeated for the remaining four 
transcripts.  
Looking for patterns 
across cases 
Finally, the researcher looked for connections and patterns 
across transcripts which allowed for the development of 
super-ordinate themes. 
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Appendix 2.17   Quality Assurance 
 
Owing to the subjective nature of qualitative research, it is essential to demonstrate 
factors that are characteristic of high quality qualitative research. These include 
sensitivity to context; commitment and rigour, transparency and coherence, and 
impact and importance (Yardley, 2000). 
 
Sensitivity to 
context 
Demonstrated by offering telephone interviews based on knowledge 
of literature that illustrates that caregivers’ have competing 
demands and little time for their own activities. Similarly, in 
recognition of the physical uncertainty that surrounds HSCT, it was 
made clear that participation would have no bearing on their loved 
one’s medical care in any way. 
 
Commitment Demonstrated by the researcher immersing herself both in the 
theoretical literature of the topic area and in the raw data. Rigour 
was demonstrated by reaching data saturation and in turn, 
illustrating the prevalence of themes across participants. Smith et 
al., (2009) suggests a sample between four and eight should provide 
extracts from at least three participants for each theme (See 
Appendix 2.18 for illustration of theme recurrence). Triangulation of 
the data was also used to ensure the researchers understanding of 
the participant’s experiences was not based solely on her own 
perspective, increasing the validity of the results. 
 
Transparency 
and coherence  
Demonstrated by detailing the data collection process and 
presenting an excerpt of the data from which readers can begin to 
understand how the researcher interpreted the data and arrived at 
the chosen themes. In addition, in the process of IPA, the researcher 
plays an active role in interpreting the data (Smith et al., 2009). It 
has been acknowledged that "inevitably the analysis is a joint 
product of the participants and analyst, the end result is always an 
account of how the analyst thinks the participant is thinking”. (Smith 
et al., 2009; p.80). Therefore the researcher practiced reflexivity 
when considering her role in the study to ensure her perspectives 
were transparent from the outset. These were discussed with the 
academic and field supervisor when the project was in development 
stages. In addition, following each interview and prior to data 
analysis the researcher kept a diary of personal feelings in order to 
become aware of these with the aim of reducing potential bias 
during interpretation of the data.  
 
Impact and 
importance 
Demonstrated by suggesting an avenue for future research based on 
a combination of previous literature and current findings and 
suggesting how, based on the current findings, caregivers’ needs can 
be better met. 
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Appendix 2.18  Table of recurrence of super-ordinate themes 
 
Super-ordinate themes Participant 
1 - Liz 
Participant 
2 - Ange 
Participant 
3 - Katie 
Participant 
4 -Paula 
Participant 
5 - Tina 
Noticing change YES YES YES YES YES 
Managing expectations YES YES YES YES YES 
Managing personal feelings YES YES YES NO YES 
Commitment  YES YES YES YES YES 
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